enchanted_elixir
𝕸𝖊𝖗𝖈𝖊𝖓𝖆𝖗𝖞 𝕮𝖔𝖗𝖕 • 𝟐𝟎𝟐𝟐🥉
Contributor
- Joined
- Apr 15, 2022
- Posts
- 24,383
- Reputation
- 43,415
THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 3: THE LIST OF COMPOUNDS
PART 8 OF 11 | PSYCHEDELIC COGNITIVE RESET & HIGH-RISK GABAERGIC CALM
VOLUME 3: THE LIST OF COMPOUNDS
PART 8 OF 11 | PSYCHEDELIC COGNITIVE RESET & HIGH-RISK GABAERGIC CALM
Chapter 25 — Psychedelics and Cognitive Change
Classic psychedelics activate serotonin 5-HT2A receptors and temporarily alter perception, self-modeling, emotional salience, and communication between brain networks. They can make the brain less rigid, but less rigid is not automatically more intelligent. A locked door has become easier to open; that does not tell you whether the room behind it contains a useful correction, an ordinary memory, or a delusion. People sometimes use psychedelics to reinvent themselves because these states can weaken—or temporarily dissolve—the familiar “you” program that ordinarily interprets reality all day. That can expose assumptions that were mistaken for facts, but it can also make nonsense feel cosmically important.
25.1 5-HT2A Signaling and Network Destabilization
5-HT2A receptors are G-protein-coupled receptors expressed heavily in the cortex. Strong activation changes how much confidence the brain assigns to familiar predictions versus incoming sensation and unusual associations. Imagine the brain's ordinary model of reality as a strict editor that rejects most interpretations before they enter awareness. A psychedelic temporarily weakens that editor, letting color, memory, emotion, bodily sensation, and distant associations compete more loudly.
That can permit revision of a rigid belief or let confusion masquerade as discovery. Plasticity means the brain is more capable of changing in response to experience; it does not mean every change is beneficial. The state increases the importance of what surrounds the user, what they repeatedly attend to, and what they rehearse afterward.
25.2 Major Psychedelic Classes
- Tryptamines: psilocybin/psilocin, N,N-DMT, and 5-MeO-DMT.
- Ergolines: LSD and related lysergamides.
- Phenethylamines: mescaline and synthetic relatives.
- Iboga alkaloids: ibogaine and noribogaine, with unusually broad pharmacology and cardiac risk.
- Non-hallucinogenic psychoplastogens: experimental compounds intended to preserve plasticity while reducing the acute psychedelic state.
25.3 Tryptamines
25.3.1 Psilocybin / Psilocin — A Six-Hour Destabilization of Ordinary Perception, Not an Acute Study Aid
What it is: Psilocybin is a phosphorylated tryptamine prodrug that is rapidly converted into psilocin, the principal psychoactive 5-HT2A agonist. Purified pharmaceutical psilocybin and dried mushrooms are not dose-equivalent products: mushroom species, specimen, storage, and preparation can change alkaloid exposure substantially.
What it may feel like: The first hour can feel physically uncertain—nausea, yawning, chills, tension, and the sense that ordinary reality is beginning to loosen. At the peak, patterns may move, colors and music become emotionally dense, time stretches, personal problems can appear from unfamiliar angles, and the boundary between “me” and experience may soften. That can become wonder, laughter, grief, panic, paranoia, confusion, or loss of control. The therapeutic claim concerns what happens in a screened, supported process afterward, not superior cognition during the intoxication.
The simplest description: Psilocybin temporarily lowers the brain’s confidence in its usual model of the world. That can make rigid assumptions revisable, but it also makes perception and judgment less reliable.
How It Works
Psilocin is a partial agonist at serotonin 5-HT2A receptors, with activity at other serotonin receptors. Cortical signaling becomes less constrained and normally segregated networks communicate differently. This may create psychological flexibility and plasticity, but plasticity means greater changeability—not automatic improvement. A frightening, chaotic, or badly interpreted experience can also be learned.
Psilocin crosses the BBB and produces predominantly central effects, while serotonin-receptor activity and autonomic arousal contribute nausea, pupil dilation, increased pulse/BP, tremor, and temperature changes.
Dose and How It Was Studied
Modern depression trials commonly study a single 25 mg pharmaceutical psilocybin dose with preparation, hours of supervision, and follow-up support; healthy-volunteer PK studies examined 15, 25, and 30 mg or 0.3–0.6 mg/kg. These are clinical exposures, not instructions for unsupervised use. Mushroom grams cannot be reliably converted into pharmaceutical milligrams without chemical analysis.
Psilocybin/psilocin are polar enough for oral aqueous formulations, but practical exposure depends on product and stomach contents. Clinical studies use standardized capsules under protocol conditions. Fasting may speed onset and food may slow it, but an empty stomach can intensify the come-up and does not guarantee less nausea. “Lemon tek,” tea, chocolate, and raw mushrooms are different uncontrolled preparations, not bioequivalent forms.
Timing and Pharmacokinetics
Evidence and Experiences
Randomized trials support a rapid antidepressant signal in selected adults when psilocybin is paired with screening and psychological support. Blinding is difficult because the subjective effects are obvious; expectancy, therapist contact, exclusion criteria, and clinical selection limit generalization. This is evidence for a treatment package in clinical populations, not for microdosing, routine enhancement, or self-treatment in teenagers.
Experience reports consistently make the come-up more physical and uncertain than marketing does: nausea, anxiety, muscle tension, and “something irreversible is happening” can precede beauty, emotional release, insight, or laughter. Other experiences remain frightening or destabilizing. Set and setting change risk but do not guarantee outcome. Come-up anxiety discussion · First-experience account
Safety, Interactions, and Monitoring
Common acute effects include anxiety, headache, nausea, dizziness, increased BP/heart rate, fatigue, perceptual distortion, and impaired judgment. Stop ordinary activity and seek urgent help for chest pain, seizure, dangerous agitation, persistent psychosis, suicidality, severe confusion, hyperthermia, or inability to maintain safety. Rare persistent perceptual symptoms or prolonged mania/psychosis require evaluation.
Major cautions include personal or strong family history of psychosis or bipolar mania, uncontrolled cardiovascular disease, pregnancy/breastfeeding, minors, seizure vulnerability, and unstable suicidality. Lithium has concerning case reports involving seizures and severe reactions; MAO inhibitors, serotonergic drugs, stimulants, tramadol, and other psychedelics complicate risk. Medication changes for a trial require the prescriber—not abrupt discontinuation. Classic physical dependence is not expected, but tolerance develops rapidly; cycling does not make psychological destabilization safe. Product-quality risks include misidentified mushrooms, uneven potency, adulterated edibles, microbes, pesticides, and undeclared drugs. Monitor mood, sleep, anxiety, BP/pulse, persistent perception changes, mania, functioning, and whether alleged “insights” remain coherent after sobriety.
Bottom Line
Psilocybin can create a vivid window in which entrenched beliefs feel less fixed, and supervised trials show meaningful antidepressant potential. During the acute state, however, cognition and judgment are destabilized—not upgraded. The container, screening, product standardization, and integration are part of the intervention.
What it is: Psilocybin is a phosphorylated tryptamine prodrug that is rapidly converted into psilocin, the principal psychoactive 5-HT2A agonist. Purified pharmaceutical psilocybin and dried mushrooms are not dose-equivalent products: mushroom species, specimen, storage, and preparation can change alkaloid exposure substantially.
What it may feel like: The first hour can feel physically uncertain—nausea, yawning, chills, tension, and the sense that ordinary reality is beginning to loosen. At the peak, patterns may move, colors and music become emotionally dense, time stretches, personal problems can appear from unfamiliar angles, and the boundary between “me” and experience may soften. That can become wonder, laughter, grief, panic, paranoia, confusion, or loss of control. The therapeutic claim concerns what happens in a screened, supported process afterward, not superior cognition during the intoxication.
The simplest description: Psilocybin temporarily lowers the brain’s confidence in its usual model of the world. That can make rigid assumptions revisable, but it also makes perception and judgment less reliable.
How It Works
Psilocin is a partial agonist at serotonin 5-HT2A receptors, with activity at other serotonin receptors. Cortical signaling becomes less constrained and normally segregated networks communicate differently. This may create psychological flexibility and plasticity, but plasticity means greater changeability—not automatic improvement. A frightening, chaotic, or badly interpreted experience can also be learned.
Psilocin crosses the BBB and produces predominantly central effects, while serotonin-receptor activity and autonomic arousal contribute nausea, pupil dilation, increased pulse/BP, tremor, and temperature changes.
Dose and How It Was Studied
Modern depression trials commonly study a single 25 mg pharmaceutical psilocybin dose with preparation, hours of supervision, and follow-up support; healthy-volunteer PK studies examined 15, 25, and 30 mg or 0.3–0.6 mg/kg. These are clinical exposures, not instructions for unsupervised use. Mushroom grams cannot be reliably converted into pharmaceutical milligrams without chemical analysis.
Psilocybin/psilocin are polar enough for oral aqueous formulations, but practical exposure depends on product and stomach contents. Clinical studies use standardized capsules under protocol conditions. Fasting may speed onset and food may slow it, but an empty stomach can intensify the come-up and does not guarantee less nausea. “Lemon tek,” tea, chocolate, and raw mushrooms are different uncontrolled preparations, not bioequivalent forms.
Timing and Pharmacokinetics
- Subjective onset: Usually 20–60 minutes orally; food and preparation can delay it.
- Pharmacologic onset / Tmax: Psilocin Tmax is commonly about 1.8–2.2 hours, with broader reports up to four hours.
- Absorption/bioavailability: Psilocybin is rapidly dephosphorylated; oral psilocin bioavailability has been estimated around 53%, with substantial variability.
- Full practical effect: The psychedelic peak usually occupies roughly hours one through three.
- Subjective duration: Mean controlled-study duration is about 5.5–6.4 hours, followed by a variable afterglow or fatigue.
- Half-life: Psilocin is roughly 1.5–3 hours in most modern human studies.
- Accumulation/steady state: It is not used to achieve steady state. Closely repeated exposure produces rapid short-term tolerance, probably involving 5-HT2A adaptation.
- Near-complete elimination: Most parent active exposure should decline substantially within roughly 8–15 hours by five half-lives, although sleep, mood, and psychological effects can last much longer.
- Metabolism/elimination: Psilocin undergoes glucuronidation and oxidative metabolism; metabolites are eliminated predominantly through urine.
Evidence and Experiences
Randomized trials support a rapid antidepressant signal in selected adults when psilocybin is paired with screening and psychological support. Blinding is difficult because the subjective effects are obvious; expectancy, therapist contact, exclusion criteria, and clinical selection limit generalization. This is evidence for a treatment package in clinical populations, not for microdosing, routine enhancement, or self-treatment in teenagers.
Experience reports consistently make the come-up more physical and uncertain than marketing does: nausea, anxiety, muscle tension, and “something irreversible is happening” can precede beauty, emotional release, insight, or laughter. Other experiences remain frightening or destabilizing. Set and setting change risk but do not guarantee outcome. Come-up anxiety discussion · First-experience account
Safety, Interactions, and Monitoring
Common acute effects include anxiety, headache, nausea, dizziness, increased BP/heart rate, fatigue, perceptual distortion, and impaired judgment. Stop ordinary activity and seek urgent help for chest pain, seizure, dangerous agitation, persistent psychosis, suicidality, severe confusion, hyperthermia, or inability to maintain safety. Rare persistent perceptual symptoms or prolonged mania/psychosis require evaluation.
Major cautions include personal or strong family history of psychosis or bipolar mania, uncontrolled cardiovascular disease, pregnancy/breastfeeding, minors, seizure vulnerability, and unstable suicidality. Lithium has concerning case reports involving seizures and severe reactions; MAO inhibitors, serotonergic drugs, stimulants, tramadol, and other psychedelics complicate risk. Medication changes for a trial require the prescriber—not abrupt discontinuation. Classic physical dependence is not expected, but tolerance develops rapidly; cycling does not make psychological destabilization safe. Product-quality risks include misidentified mushrooms, uneven potency, adulterated edibles, microbes, pesticides, and undeclared drugs. Monitor mood, sleep, anxiety, BP/pulse, persistent perception changes, mania, functioning, and whether alleged “insights” remain coherent after sobriety.
Bottom Line
Psilocybin can create a vivid window in which entrenched beliefs feel less fixed, and supervised trials show meaningful antidepressant potential. During the acute state, however, cognition and judgment are destabilized—not upgraded. The container, screening, product standardization, and integration are part of the intervention.
25.3.2 N,N-DMT — A Near-Instant Visual Reality Replacement That Clears in Minutes
What it is: N,N-dimethyltryptamine (DMT) is a short-acting tryptamine psychedelic and serotonin-receptor agonist. Route changes the drug completely: inhaled or intravenous DMT produces a minute-scale state, while oral DMT is ordinarily destroyed by monoamine oxidase A (MAO-A) unless paired with an MAO inhibitor, as in ayahuasca.
What it may feel like: Inhaled or bolus exposure can replace the room before a person has time to orient: geometric motion becomes immersive space, body awareness fragments, language stops working, and apparently autonomous “entities” or environments may feel more real than imagination. Awe and astonishment can coexist with panic, chest awareness, fear of death, or the certainty that one has permanently broken reality. The return is unusually fast, but psychological certainty about what happened can outlast the molecule.
The simplest description: DMT does not gently distort the current scene; at sufficient exposure it can replace the brain’s entire working model of the scene, then return ordinary perception within half an hour.
How It Works
DMT acts primarily through 5-HT2A and other serotonin receptors. It is highly brain penetrant and is redistributed and metabolized extremely quickly. Claims that sigma-1 activity explains the psychedelic experience or that endogenous DMT proves a spiritual function remain speculative.
MAO-A rapidly converts DMT toward indole-3-acetic-acid-related metabolites. Blocking MAO-A turns otherwise inactive oral DMT into a much longer, interaction-heavy exposure; ayahuasca therefore cannot inherit smoked-DMT timing or safety assumptions.
Dose and How It Was Studied
Controlled studies have administered known DMT amounts by intravenous bolus or infusion; a 2023 trial used 9–21.5 mg freebase over ten minutes, and later bolus research studied 5–20 mg. These are monitored research exposures—not instructions for inhalation, ayahuasca, or home injection.
Freebase DMT is lipophilic and poorly water soluble; clinical IV work uses validated salts and sterile formulations. Heating, vaping efficiency, combustion loss, device temperature, and inhalation technique make a weighed freebase amount an unreliable delivered dose. Oral use with MAO inhibition creates a separate pharmacologic system and requires its own interaction analysis.
Timing and Pharmacokinetics
Evidence and Experiences
Modern human studies establish route-specific kinetics and a controllable psychedelic state; therapeutic efficacy remains early and cannot be inferred from intensity. Bolus administration produces more anxiety and negative effects than gradual infusion in controlled work.
Experience reports repeatedly distinguish “seeing visuals” from a breakthrough in which ordinary surroundings, body, and biography disappear. Reports of entities, death/rebirth, cosmic certainty, terror, and immediate sobriety are common themes, not verified external events. Product identity, inhaled delivery, expectation, and selection bias prevent incidence estimates.
Safety, Interactions, and Monitoring
Acute risks include panic, hypertension/tachycardia, vomiting, impaired coordination, accidental injury, loss of airway protection, and dangerous behavior while disoriented. Seek urgent help for seizure, chest pain, hyperthermia, persistent psychosis, suicidality, severe agitation, aspiration, or failure to regain ordinary responsiveness.
MAO inhibitors radically increase interaction risk with serotonergic drugs, stimulants, decongestants, tramadol, some opioids, and many psychiatric medications. Bipolar mania, psychosis vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, and minors are major contraindication domains. Physical dependence is not expected; tolerance is less straightforward than with longer psychedelics, and repetition can still destabilize sleep, mood, or reality testing. Product-quality risks include wrong salt/freebase, residual solvents, plant contaminants, and mislabeled blends. Monitor mood, sleep, persistent perceptual changes, mania, anxiety, BP/pulse, and sober functioning.
Bottom Line
DMT is a brief but potentially total replacement of ordinary conscious structure. Its short plasma life reduces session length, not psychological intensity or interaction risk—especially once MAO inhibition converts it into a different drug experience.
What it is: N,N-dimethyltryptamine (DMT) is a short-acting tryptamine psychedelic and serotonin-receptor agonist. Route changes the drug completely: inhaled or intravenous DMT produces a minute-scale state, while oral DMT is ordinarily destroyed by monoamine oxidase A (MAO-A) unless paired with an MAO inhibitor, as in ayahuasca.
What it may feel like: Inhaled or bolus exposure can replace the room before a person has time to orient: geometric motion becomes immersive space, body awareness fragments, language stops working, and apparently autonomous “entities” or environments may feel more real than imagination. Awe and astonishment can coexist with panic, chest awareness, fear of death, or the certainty that one has permanently broken reality. The return is unusually fast, but psychological certainty about what happened can outlast the molecule.
The simplest description: DMT does not gently distort the current scene; at sufficient exposure it can replace the brain’s entire working model of the scene, then return ordinary perception within half an hour.
How It Works
DMT acts primarily through 5-HT2A and other serotonin receptors. It is highly brain penetrant and is redistributed and metabolized extremely quickly. Claims that sigma-1 activity explains the psychedelic experience or that endogenous DMT proves a spiritual function remain speculative.
MAO-A rapidly converts DMT toward indole-3-acetic-acid-related metabolites. Blocking MAO-A turns otherwise inactive oral DMT into a much longer, interaction-heavy exposure; ayahuasca therefore cannot inherit smoked-DMT timing or safety assumptions.
Dose and How It Was Studied
Controlled studies have administered known DMT amounts by intravenous bolus or infusion; a 2023 trial used 9–21.5 mg freebase over ten minutes, and later bolus research studied 5–20 mg. These are monitored research exposures—not instructions for inhalation, ayahuasca, or home injection.
Freebase DMT is lipophilic and poorly water soluble; clinical IV work uses validated salts and sterile formulations. Heating, vaping efficiency, combustion loss, device temperature, and inhalation technique make a weighed freebase amount an unreliable delivered dose. Oral use with MAO inhibition creates a separate pharmacologic system and requires its own interaction analysis.
Timing and Pharmacokinetics
- Subjective onset: Seconds to a few minutes after inhalation or IV bolus; slower during controlled infusion.
- Pharmacologic onset / Tmax: IV bolus peaks essentially immediately; a ten-minute infusion reaches its peak near the end of infusion.
- Absorption/bioavailability: IV is complete by definition; inhaled bioavailability is variable and inadequately quantified; oral DMT alone is usually negligible because of MAO-A.
- Full practical effect: Bolus peak occurs within the first two to five minutes; infusion can sustain a plateau.
- Subjective duration: Bolus/inhaled effects commonly resolve in 12–30 minutes; infusion lasts as long as exposure is maintained, and ayahuasca lasts hours.
- Half-life: Human IV estimates range roughly 5–19 minutes, with early and terminal phases.
- Accumulation/steady state: Bolus use does not reach steady state; controlled infusion can sustain exposure, and acute tolerance may appear during prolonged infusion.
- Near-complete elimination: Plasma DMT falls rapidly over approximately one to two hours, although redistribution and psychological effects complicate a literal five-half-life rule.
- Metabolism/elimination: Rapid MAO-A-mediated oxidative deamination, with CYP2D6/2C19 contributions; metabolites are excreted primarily in urine.
Evidence and Experiences
Modern human studies establish route-specific kinetics and a controllable psychedelic state; therapeutic efficacy remains early and cannot be inferred from intensity. Bolus administration produces more anxiety and negative effects than gradual infusion in controlled work.
Experience reports repeatedly distinguish “seeing visuals” from a breakthrough in which ordinary surroundings, body, and biography disappear. Reports of entities, death/rebirth, cosmic certainty, terror, and immediate sobriety are common themes, not verified external events. Product identity, inhaled delivery, expectation, and selection bias prevent incidence estimates.
Safety, Interactions, and Monitoring
Acute risks include panic, hypertension/tachycardia, vomiting, impaired coordination, accidental injury, loss of airway protection, and dangerous behavior while disoriented. Seek urgent help for seizure, chest pain, hyperthermia, persistent psychosis, suicidality, severe agitation, aspiration, or failure to regain ordinary responsiveness.
MAO inhibitors radically increase interaction risk with serotonergic drugs, stimulants, decongestants, tramadol, some opioids, and many psychiatric medications. Bipolar mania, psychosis vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, and minors are major contraindication domains. Physical dependence is not expected; tolerance is less straightforward than with longer psychedelics, and repetition can still destabilize sleep, mood, or reality testing. Product-quality risks include wrong salt/freebase, residual solvents, plant contaminants, and mislabeled blends. Monitor mood, sleep, persistent perceptual changes, mania, anxiety, BP/pulse, and sober functioning.
Bottom Line
DMT is a brief but potentially total replacement of ordinary conscious structure. Its short plasma life reduces session length, not psychological intensity or interaction risk—especially once MAO inhibition converts it into a different drug experience.
25.3.3 5-MeO-DMT — Less Visual Narrative, More Abrupt Loss of Self
What it is: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, mebufotenin) is a very short-acting serotonergic psychedelic with strong 5-HT1A and 5-HT2A activity. It is pharmacologically distinct from N,N-DMT and from bufotenine, although CYP2D6 can convert some 5-MeO-DMT into bufotenine.
What it may feel like: Rather than entering a detailed geometric world, a person may feel the observer itself disappear: body, name, time, and the distinction between self and everything else collapse into white light, unity, void, or terror. There may be screaming, thrashing, vomiting, apparent unconsciousness, or respiratory irregularity even when the person later reports peace. The return can bring gratitude and clarity—or panic, derealization, insomnia, and frightening spontaneous “reactivations.”
The simplest description: N,N-DMT is often described as going somewhere; 5-MeO-DMT is more often described as the “someone” who could go anywhere ceasing to exist.
How It Works
5-MeO-DMT is a broad serotonin-receptor agonist with especially important 5-HT1A and 5-HT2A signaling. It readily crosses the BBB. The relative lack of elaborate visuals does not mean the experience is milder; ego dissolution and autonomic effects can be more abrupt.
MAO-A is a major clearance pathway, while CYP2D6-mediated O-demethylation can produce active bufotenine. Genetic CYP2D6 variation and MAO inhibition can therefore change exposure and risk. Oral activity is weak without an MAO inhibitor, but combining the two can dangerously prolong and intensify serotonergic exposure.
Dose and How It Was Studied
A Phase I trial studied 1–12 mg of a proprietary intranasal benzoate formulation (BPL-003) in 44 healthy participants. Other clinical programs use standardized vaporized formulations. These product-specific milligram amounts cannot be transferred to freebase, toad secretion, homemade nasal preparations, or another salt.
The freebase is lipophilic and poorly suited to water; salts and proprietary formulations behave differently. Only the tested formulation defines its absorption. Natural secretion is chemically variable and may contain other compounds or contaminants; it is neither standardized nor safer because it is “natural.”
Timing and Pharmacokinetics
Evidence and Experiences
Phase I work provides real human PK and controlled evidence of profound ego dissolution, but efficacy claims remain preliminary and formulation-specific. Observational reports of depression or trauma improvement cannot isolate selection, expectation, facilitation, or natural recovery.
Forum and retreat reports describe unity, nonduality, death, rebirth, terror, suffocation, bliss, involuntary movement, vomiting, and delayed reactivations. Because outward immobility may coexist with inward distress—and violent movement may coexist with a later positive report—a sober trained monitor and physical environment matter. Anecdotes cannot prove safety or therapeutic benefit.
Safety, Interactions, and Monitoring
Acute dangers include loss of consciousness, aspiration, respiratory compromise, vomiting, panic, traumatic movement, hypertension/tachycardia, hyperthermia, and serotonin toxicity. Urgent evaluation is warranted for seizure, chest pain, breathing difficulty, persistent unresponsiveness, severe agitation, hyperthermia, psychosis, or suicidality.
Do not combine with MAO inhibitors. Serotonergic antidepressants, tramadol, stimulants, lithium, other psychedelics, and many psychiatric drugs require professional review. Psychosis or bipolar vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, minors, and unstable mental health are major cautions. Physical dependence is not expected, but the absence of classic withdrawal does not prevent psychological destabilization or compulsive repetition. Product-quality testing must distinguish exact compound, salt/freebase, concentration, residual solvents, and adulterants. Monitor breathing during the acute state and mood, sleep, derealization, mania, persistent perception changes, and functioning afterward.
Bottom Line
5-MeO-DMT is not simply “stronger DMT.” It is a distinct, extremely rapid state dominated by loss of self rather than visual narrative. A sub-half-hour experience can still produce medical emergencies or weeks of psychological disturbance.
What it is: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, mebufotenin) is a very short-acting serotonergic psychedelic with strong 5-HT1A and 5-HT2A activity. It is pharmacologically distinct from N,N-DMT and from bufotenine, although CYP2D6 can convert some 5-MeO-DMT into bufotenine.
What it may feel like: Rather than entering a detailed geometric world, a person may feel the observer itself disappear: body, name, time, and the distinction between self and everything else collapse into white light, unity, void, or terror. There may be screaming, thrashing, vomiting, apparent unconsciousness, or respiratory irregularity even when the person later reports peace. The return can bring gratitude and clarity—or panic, derealization, insomnia, and frightening spontaneous “reactivations.”
The simplest description: N,N-DMT is often described as going somewhere; 5-MeO-DMT is more often described as the “someone” who could go anywhere ceasing to exist.
How It Works
5-MeO-DMT is a broad serotonin-receptor agonist with especially important 5-HT1A and 5-HT2A signaling. It readily crosses the BBB. The relative lack of elaborate visuals does not mean the experience is milder; ego dissolution and autonomic effects can be more abrupt.
MAO-A is a major clearance pathway, while CYP2D6-mediated O-demethylation can produce active bufotenine. Genetic CYP2D6 variation and MAO inhibition can therefore change exposure and risk. Oral activity is weak without an MAO inhibitor, but combining the two can dangerously prolong and intensify serotonergic exposure.
Dose and How It Was Studied
A Phase I trial studied 1–12 mg of a proprietary intranasal benzoate formulation (BPL-003) in 44 healthy participants. Other clinical programs use standardized vaporized formulations. These product-specific milligram amounts cannot be transferred to freebase, toad secretion, homemade nasal preparations, or another salt.
The freebase is lipophilic and poorly suited to water; salts and proprietary formulations behave differently. Only the tested formulation defines its absorption. Natural secretion is chemically variable and may contain other compounds or contaminants; it is neither standardized nor safer because it is “natural.”
Timing and Pharmacokinetics
- Subjective onset: Seconds to several minutes when vaporized; usually several minutes intranasally.
- Pharmacologic onset / Tmax: Intranasal BPL-003 reached median Tmax around 8–10 minutes.
- Absorption/bioavailability: Route- and formulation-dependent; absolute human bioavailability is not adequately established across products.
- Full practical effect: Vaporized effects can become overwhelming within one to five minutes; intranasal peak is slower.
- Subjective duration: Vaporized experiences are often 10–30 minutes; intranasal effects can occupy roughly 45–90 minutes.
- Half-life: Mean terminal half-life for the intranasal formulation was under 27 minutes.
- Accumulation/steady state: Not a steady-state drug. Closely repeated individualized dosing has been studied clinically, but consumer tolerance/sensitization is not adequately defined.
- Near-complete elimination: Parent exposure should fall greatly within roughly two to three hours, while sleep, anxiety, derealization, or reactivation can persist.
- Metabolism/elimination: Primarily MAO-A oxidative deamination, with CYP2D6 conversion to bufotenine; urinary recovery of unchanged drug is low.
Evidence and Experiences
Phase I work provides real human PK and controlled evidence of profound ego dissolution, but efficacy claims remain preliminary and formulation-specific. Observational reports of depression or trauma improvement cannot isolate selection, expectation, facilitation, or natural recovery.
Forum and retreat reports describe unity, nonduality, death, rebirth, terror, suffocation, bliss, involuntary movement, vomiting, and delayed reactivations. Because outward immobility may coexist with inward distress—and violent movement may coexist with a later positive report—a sober trained monitor and physical environment matter. Anecdotes cannot prove safety or therapeutic benefit.
Safety, Interactions, and Monitoring
Acute dangers include loss of consciousness, aspiration, respiratory compromise, vomiting, panic, traumatic movement, hypertension/tachycardia, hyperthermia, and serotonin toxicity. Urgent evaluation is warranted for seizure, chest pain, breathing difficulty, persistent unresponsiveness, severe agitation, hyperthermia, psychosis, or suicidality.
Do not combine with MAO inhibitors. Serotonergic antidepressants, tramadol, stimulants, lithium, other psychedelics, and many psychiatric drugs require professional review. Psychosis or bipolar vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, minors, and unstable mental health are major cautions. Physical dependence is not expected, but the absence of classic withdrawal does not prevent psychological destabilization or compulsive repetition. Product-quality testing must distinguish exact compound, salt/freebase, concentration, residual solvents, and adulterants. Monitor breathing during the acute state and mood, sleep, derealization, mania, persistent perception changes, and functioning afterward.
Bottom Line
5-MeO-DMT is not simply “stronger DMT.” It is a distinct, extremely rapid state dominated by loss of self rather than visual narrative. A sub-half-hour experience can still produce medical emergencies or weeks of psychological disturbance.
25.4 Ergolines
25.4.1 LSD — Twelve Hours of Amplified Salience, Patterning, and Cognitive Momentum
What it is: Lysergic acid diethylamide (LSD) is an extraordinarily potent ergoline psychedelic active in microgram quantities. It engages 5-HT2A and multiple serotonin, dopamine, and adrenergic receptors, giving it a longer and often more stimulating profile than psilocybin.
What it may feel like: The onset can feel like rising voltage: colors sharpen, surfaces breathe, music becomes spatial, thoughts connect across unusual distances, and ordinary events feel charged with meaning. The same momentum can become looping analysis, paranoia, jaw or muscle tension, inability to sleep, and twelve hours of being unable to “turn it off.” A positive afterglow may feel clear and energetic the next day; an equally real aftermath is exhaustion, anxiety, disconnection, or low mood.
The simplest description: LSD increases the gain on perception, association, and significance for most of a day. It can make ideas feel profound faster than it can verify whether they are true.
How It Works
LSD is a potent partial agonist at 5-HT2A receptors and interacts with other serotonergic, dopaminergic, and adrenergic targets. Slow receptor dissociation and downstream signaling help explain why subjective effects outlast the short plasma peak. It crosses the BBB readily and affects both cortical networks and peripheral autonomic function.
Dose and How It Was Studied
Modern healthy-volunteer studies have tested standardized 50–200 micrograms, while microdose PK studies examined 5–20 micrograms. Clinical anxiety/depression programs use pharmaceutical material, screening, all-day supervision, and follow-up. These are research exposures, not unsupervised instructions. A blotter’s claimed microgram content is rarely analytically verified.
LSD salts are sufficiently water compatible for pharmaceutical solutions, but light, heat, moisture, and chlorine can degrade material. Blotter, liquid, and tablets are not reliably dose-equivalent without testing. Food is not required; a heavy meal may delay the felt onset, but fasting does not improve safety.
Solubility and practical administration: LSD free base is poorly suited to casual aqueous handling, while the tartrate salt used in research is water-soluble; both are active in microgram quantities and are highly light-sensitive. Solubility does not make blotter or liquid concentration trustworthy, and food timing is less important than verified identity and the impossibility of safely eyeballing a dose.
Timing and Pharmacokinetics
Evidence and Experiences
Controlled studies clearly establish psychedelic and autonomic effects. Therapeutic signals exist for anxiety and depression, but expectancy and functional unblinding remain major limitations. Placebo-controlled microdosing studies do not support the broad productivity and creativity claims found online, and even low doses can provoke anxiety.
Forum reports vividly distinguish LSD from psilocybin: more mental stimulation, more geometric precision, greater susceptibility to thought loops, and a much longer runway before sleep. Some users report days of clarity; others report next-day paranoia, exhaustion, and emotional disconnection. What LSD feels like · Mixed next-day effects
Safety, Interactions, and Monitoring
Common acute effects include anxiety, nausea, headache, pupil dilation, increased BP/heart rate, tremor, jaw tension, temperature change, and insomnia. Urgent help is warranted for seizure, chest pain, hyperthermia, dangerous agitation, suicidality, persistent psychosis, severe confusion, or inability to remain physically safe.
Major cautions include psychosis or bipolar vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, minors, and unstable mental health. Lithium has concerning reports involving seizures and severe reactions; serotonergic drugs, MAO inhibitors, stimulants, tramadol, and other psychedelics require professional review. Physical dependence is not expected, but rapid tolerance does not prevent compulsive repetition or psychological destabilization. Product-quality testing is critical because NBOMe and DOx compounds can be sold as LSD and may differ in toxicity and duration. Track sleep, mood, mania, anxiety, BP/pulse, persistent perception changes, and whether insights remain coherent when sober.
Bottom Line
LSD is best understood as all-day amplification of salience and cognitive momentum, not a clean creativity pill. Its length is a defining pharmacologic effect, and the feeling that an idea is cosmically important is not evidence that it survives ordinary scrutiny.
What it is: Lysergic acid diethylamide (LSD) is an extraordinarily potent ergoline psychedelic active in microgram quantities. It engages 5-HT2A and multiple serotonin, dopamine, and adrenergic receptors, giving it a longer and often more stimulating profile than psilocybin.
What it may feel like: The onset can feel like rising voltage: colors sharpen, surfaces breathe, music becomes spatial, thoughts connect across unusual distances, and ordinary events feel charged with meaning. The same momentum can become looping analysis, paranoia, jaw or muscle tension, inability to sleep, and twelve hours of being unable to “turn it off.” A positive afterglow may feel clear and energetic the next day; an equally real aftermath is exhaustion, anxiety, disconnection, or low mood.
The simplest description: LSD increases the gain on perception, association, and significance for most of a day. It can make ideas feel profound faster than it can verify whether they are true.
How It Works
LSD is a potent partial agonist at 5-HT2A receptors and interacts with other serotonergic, dopaminergic, and adrenergic targets. Slow receptor dissociation and downstream signaling help explain why subjective effects outlast the short plasma peak. It crosses the BBB readily and affects both cortical networks and peripheral autonomic function.
Dose and How It Was Studied
Modern healthy-volunteer studies have tested standardized 50–200 micrograms, while microdose PK studies examined 5–20 micrograms. Clinical anxiety/depression programs use pharmaceutical material, screening, all-day supervision, and follow-up. These are research exposures, not unsupervised instructions. A blotter’s claimed microgram content is rarely analytically verified.
LSD salts are sufficiently water compatible for pharmaceutical solutions, but light, heat, moisture, and chlorine can degrade material. Blotter, liquid, and tablets are not reliably dose-equivalent without testing. Food is not required; a heavy meal may delay the felt onset, but fasting does not improve safety.
Solubility and practical administration: LSD free base is poorly suited to casual aqueous handling, while the tartrate salt used in research is water-soluble; both are active in microgram quantities and are highly light-sensitive. Solubility does not make blotter or liquid concentration trustworthy, and food timing is less important than verified identity and the impossibility of safely eyeballing a dose.
Timing and Pharmacokinetics
- Subjective onset: Usually 30–90 minutes, sometimes longer.
- Pharmacologic onset / Tmax: Oral Tmax is approximately 1.5–2 hours.
- Absorption/bioavailability: Well absorbed; oral bioavailability is commonly estimated near 70%, with meaningful variability.
- Full practical effect: Peak subjective effects usually occupy approximately hours two through five.
- Subjective duration: Commonly 8–12 hours, with residual stimulation or insomnia extending to 16 hours in some people.
- Half-life: Modern human estimates are roughly 2.6–4 hours, depending on study and dose.
- Accumulation/steady state: It is not a steady-state intervention. Rapid psychedelic tolerance and cross-tolerance develop over consecutive days.
- Near-complete elimination: Most parent exposure declines over roughly 13–20 hours by five half-lives, matching the need to reserve the entire day and following sleep period.
- Metabolism/elimination: Hepatic metabolism produces inactive 2-oxo-3-hydroxy-LSD and related metabolites, excreted mainly in urine.
Evidence and Experiences
Controlled studies clearly establish psychedelic and autonomic effects. Therapeutic signals exist for anxiety and depression, but expectancy and functional unblinding remain major limitations. Placebo-controlled microdosing studies do not support the broad productivity and creativity claims found online, and even low doses can provoke anxiety.
Forum reports vividly distinguish LSD from psilocybin: more mental stimulation, more geometric precision, greater susceptibility to thought loops, and a much longer runway before sleep. Some users report days of clarity; others report next-day paranoia, exhaustion, and emotional disconnection. What LSD feels like · Mixed next-day effects
Safety, Interactions, and Monitoring
Common acute effects include anxiety, nausea, headache, pupil dilation, increased BP/heart rate, tremor, jaw tension, temperature change, and insomnia. Urgent help is warranted for seizure, chest pain, hyperthermia, dangerous agitation, suicidality, persistent psychosis, severe confusion, or inability to remain physically safe.
Major cautions include psychosis or bipolar vulnerability, cardiovascular disease, seizure history, pregnancy/breastfeeding, minors, and unstable mental health. Lithium has concerning reports involving seizures and severe reactions; serotonergic drugs, MAO inhibitors, stimulants, tramadol, and other psychedelics require professional review. Physical dependence is not expected, but rapid tolerance does not prevent compulsive repetition or psychological destabilization. Product-quality testing is critical because NBOMe and DOx compounds can be sold as LSD and may differ in toxicity and duration. Track sleep, mood, mania, anxiety, BP/pulse, persistent perception changes, and whether insights remain coherent when sober.
Bottom Line
LSD is best understood as all-day amplification of salience and cognitive momentum, not a clean creativity pill. Its length is a defining pharmacologic effect, and the feeling that an idea is cosmically important is not evidence that it survives ordinary scrutiny.
25.5 Phenethylamines
25.5.1 Mescaline — A Slow, Warm, Physically Demanding Psychedelic That Can Last Fifteen Hours
What it is: Mescaline is 3,4,5-trimethoxyphenethylamine, a classic 5-HT2A psychedelic found in peyote and San Pedro–type cacti and also produced synthetically. Pharmaceutical mescaline hydrochloride and cactus material are not dose-equivalent: plant alkaloid content and accompanying compounds vary widely.
What it may feel like: The come-up is slow and bodily—nausea, stomach pressure, chills, stimulation, and waiting—before colors become luminous, surfaces gain patterned depth, and emotion feels open, warm, and socially connected. Compared with LSD, many reports describe less sharp cognitive machinery and more embodied appreciation. The long duration can also become exhausting, anxious, hypertensive, or impossible to sleep through.
The simplest description: Mescaline is a long sunrise rather than a trapdoor: slower to build than DMT or psilocybin, warm and visual for many users, but physically expensive and capable of occupying the entire day and night.
How It Works
Mescaline acts mainly as a partial agonist at 5-HT2A and related serotonin receptors. It crosses the BBB but is far less potent by mass than LSD because its receptor affinity and disposition differ. Central psychedelic effects coexist with strong gastrointestinal and autonomic effects.
Dose and How It Was Studied
Modern controlled studies examined 100–800 mg of pharmaceutical mescaline hydrochloride in healthy adults. Those protocol doses cannot be converted directly to grams of fresh or dried cactus, and the upper research doses are not recommendations. Clinical screening and prolonged observation materially change the risk.
Mescaline hydrochloride is water soluble and standardized capsules/solutions can be swallowed with water. Cactus preparations contain variable material that can worsen nausea. Food may delay absorption; fasting may intensify the come-up and does not remove emesis or cardiovascular risk.
Timing and Pharmacokinetics
Evidence and Experiences
Modern studies establish dose-proportional PK, long psychedelic effects, and measurable cardiovascular changes. Therapeutic claims rely heavily on historical, observational, ceremonial, or uncontrolled evidence and cannot establish healthy cognitive enhancement.
Experience reports emphasize the unusually long, gradual arc: nausea and uncertainty can precede colorful visual depth, empathy, laughter, nature connectedness, and bodily warmth. Nonresponse, vomiting, anxiety, stimulation, and total exhaustion are also common themes. Plant identity and alkaloid variability make anecdotes especially difficult to compare.
Safety, Interactions, and Monitoring
Acute effects include nausea/vomiting, headache, anxiety, increased BP/heart rate, hyperthermia, tremor, pupil dilation, dehydration, and insomnia. In controlled administrations, diastolic BP above 100 mmHg occurred in 6%, tachycardia in 3%, and temperature above 38°C in 5%. Seek help for chest pain, seizure, hyperthermia, severe agitation, persistent psychosis, dangerous vomiting/dehydration, or suicidality.
Psychosis/bipolar vulnerability, cardiovascular disease, pregnancy/breastfeeding, minors, seizure history, and unstable mental health are major cautions. Stimulants, MAO inhibitors, serotonergic drugs, tramadol, lithium, and other psychedelics require professional review. Physical dependence is not expected; tolerance/cross-tolerance develops, and cycling does not prevent psychological risk. Product-quality checks must distinguish mescaline salt from cactus material and screen plants for identity, pesticides, microbes, and adulterants. Track BP/pulse, temperature, hydration, sleep, mood, mania, and persistent perceptual changes.
Bottom Line
Mescaline’s appeal is its gradual, warm, embodied character; its price is nausea, autonomic load, and an exceptionally long commitment. It is not a practical cognitive enhancer, and cactus grams are not a reliable dosing language.
What it is: Mescaline is 3,4,5-trimethoxyphenethylamine, a classic 5-HT2A psychedelic found in peyote and San Pedro–type cacti and also produced synthetically. Pharmaceutical mescaline hydrochloride and cactus material are not dose-equivalent: plant alkaloid content and accompanying compounds vary widely.
What it may feel like: The come-up is slow and bodily—nausea, stomach pressure, chills, stimulation, and waiting—before colors become luminous, surfaces gain patterned depth, and emotion feels open, warm, and socially connected. Compared with LSD, many reports describe less sharp cognitive machinery and more embodied appreciation. The long duration can also become exhausting, anxious, hypertensive, or impossible to sleep through.
The simplest description: Mescaline is a long sunrise rather than a trapdoor: slower to build than DMT or psilocybin, warm and visual for many users, but physically expensive and capable of occupying the entire day and night.
How It Works
Mescaline acts mainly as a partial agonist at 5-HT2A and related serotonin receptors. It crosses the BBB but is far less potent by mass than LSD because its receptor affinity and disposition differ. Central psychedelic effects coexist with strong gastrointestinal and autonomic effects.
Dose and How It Was Studied
Modern controlled studies examined 100–800 mg of pharmaceutical mescaline hydrochloride in healthy adults. Those protocol doses cannot be converted directly to grams of fresh or dried cactus, and the upper research doses are not recommendations. Clinical screening and prolonged observation materially change the risk.
Mescaline hydrochloride is water soluble and standardized capsules/solutions can be swallowed with water. Cactus preparations contain variable material that can worsen nausea. Food may delay absorption; fasting may intensify the come-up and does not remove emesis or cardiovascular risk.
Timing and Pharmacokinetics
- Subjective onset: Model-predicted onset is around one hour, commonly reported as 45–120 minutes.
- Pharmacologic onset / Tmax: Mean oral Tmax is approximately two hours.
- Absorption/bioavailability: Oral bioavailability is at least 53%, limited partly by first-pass metabolism.
- Full practical effect: Peak effects generally develop over two to four hours rather than arriving suddenly.
- Subjective duration: Dose-dependent, from roughly 3 hours at low experimental exposure to about 15 hours at high exposure.
- Half-life: Approximately 3.5 hours in modern human studies.
- Accumulation/steady state: Not a steady-state drug; consecutive psychedelic exposure produces tolerance and cross-tolerance.
- Near-complete elimination: Roughly 18 hours by five half-lives, consistent with prolonged residual stimulation.
- Metabolism/elimination: First-pass oxidation forms 3,4,5-trimethoxyphenylacetic acid; parent and metabolite are eliminated predominantly through urine.
Evidence and Experiences
Modern studies establish dose-proportional PK, long psychedelic effects, and measurable cardiovascular changes. Therapeutic claims rely heavily on historical, observational, ceremonial, or uncontrolled evidence and cannot establish healthy cognitive enhancement.
Experience reports emphasize the unusually long, gradual arc: nausea and uncertainty can precede colorful visual depth, empathy, laughter, nature connectedness, and bodily warmth. Nonresponse, vomiting, anxiety, stimulation, and total exhaustion are also common themes. Plant identity and alkaloid variability make anecdotes especially difficult to compare.
Safety, Interactions, and Monitoring
Acute effects include nausea/vomiting, headache, anxiety, increased BP/heart rate, hyperthermia, tremor, pupil dilation, dehydration, and insomnia. In controlled administrations, diastolic BP above 100 mmHg occurred in 6%, tachycardia in 3%, and temperature above 38°C in 5%. Seek help for chest pain, seizure, hyperthermia, severe agitation, persistent psychosis, dangerous vomiting/dehydration, or suicidality.
Psychosis/bipolar vulnerability, cardiovascular disease, pregnancy/breastfeeding, minors, seizure history, and unstable mental health are major cautions. Stimulants, MAO inhibitors, serotonergic drugs, tramadol, lithium, and other psychedelics require professional review. Physical dependence is not expected; tolerance/cross-tolerance develops, and cycling does not prevent psychological risk. Product-quality checks must distinguish mescaline salt from cactus material and screen plants for identity, pesticides, microbes, and adulterants. Track BP/pulse, temperature, hydration, sleep, mood, mania, and persistent perceptual changes.
Bottom Line
Mescaline’s appeal is its gradual, warm, embodied character; its price is nausea, autonomic load, and an exceptionally long commitment. It is not a practical cognitive enhancer, and cactus grams are not a reliable dosing language.
25.6 Iboga Alkaloids
25.6.1 Ibogaine / Noribogaine — A Day-Long Withdrawal-Interrupting State With Real Arrhythmia Risk
What it is: Ibogaine is a psychoactive iboga alkaloid converted mainly by CYP2D6 into noribogaine, a longer-lived active metabolite. It is investigated for substance-use disorders but is not an approved addiction treatment in the United States.
What it may feel like: The acute phase may be less like a colorful recreational trip and more like being pinned inside a lucid waking dream: buzzing, rapid autobiographical scenes, vomiting, severe imbalance, and hours of reviewing memories while the body is difficult to operate. Some opioid-dependent users report withdrawal and craving switching off with astonishing speed. Others endure terror, insomnia, arrhythmia, prolonged unreality, or no durable recovery.
The simplest description: Ibogaine may interrupt withdrawal long enough to expose a new behavioral path, but it does so while placing the heart and nervous system under a risk that cannot be judged by how calm the experience feels.
How It Works
Ibogaine and noribogaine engage multiple systems, including serotonin transporters/receptors, NMDA, nicotinic, opioid, sigma, and neurotrophic signaling. No single mechanism explains withdrawal suppression. Ibogaine and noribogaine block cardiac hERG potassium channels, delaying repolarization and prolonging QT—an electrical setup for torsades and sudden death.
CYP2D6 genotype and inhibitors can shift parent/metabolite exposure more than tenfold. Noribogaine persists far longer than ibogaine, so cardiac and drug-interaction risk can continue after the visions end.
Dose and How It Was Studied
A controlled healthy-volunteer PK study used 20 mg oral ibogaine; observational detoxification protocols have used far higher weight-based exposures. Those detox doses are not recommendations and have produced severe ataxia, bradycardia, QT prolongation, and deaths. This is not a home-detox compound.
Ibogaine hydrochloride is the more defined oral research form; total-alkaloid extracts and root bark have variable ibogaine and co-alkaloid content. Food, vomiting, extract composition, and CYP2D6 status change exposure. No solubility trick makes nonmedical dosing safe.
Timing and Pharmacokinetics
Evidence and Experiences
Observational and small clinical studies report rapid reductions in opioid withdrawal and craving, but controlled efficacy evidence is weak and cannot match the certainty of approved treatments such as buprenorphine and methadone. A treatment that sometimes works dramatically can still have an unfavorable mortality profile.
Experience reports include visions, buzzing, purging, profound autobiographical review, severe ataxia, interrupted withdrawal, and months of recovery; they also include terrifying suicidal imagery, persistent derealization, and medical emergencies. Ataxia and difficult-experience discussion · Long-term negative report
Safety, Interactions, and Monitoring
Ibogaine can cause QT prolongation, bradycardia, torsades, cardiac arrest, seizure, severe ataxia, vomiting/aspiration, electrolyte abnormalities, and death. Emergency evaluation is required for fainting, palpitations, chest pain, seizure, breathing difficulty, persistent vomiting, severe confusion, or suicidality.
It must not be combined casually with methadone or other QT-prolonging drugs, CYP2D6 inhibitors, antidepressants, antipsychotics, stimulants, antiemetics, antibiotics, or electrolyte-depleting substances. Opioid, alcohol, benzodiazepine, or stimulant withdrawal creates additional medical risk. Clinical screening requires ECG/QTc, electrolytes, liver/kidney assessment, medication review, continuous cardiac monitoring, resuscitation capacity, and trained medical staff. Dependence is not typical, and tolerance/cycling rules are not established; repetition before noribogaine clears can accumulate risk. Product-quality testing must distinguish HCl from extracts and measure alkaloids/adulterants.
Bottom Line
Ibogaine is one of the few compounds whose anecdotal effect on opioid withdrawal is dramatic enough to be scientifically compelling—and whose cardiac danger is dramatic enough to make nonmedical use indefensible. The monitoring infrastructure is part of the intervention.
What it is: Ibogaine is a psychoactive iboga alkaloid converted mainly by CYP2D6 into noribogaine, a longer-lived active metabolite. It is investigated for substance-use disorders but is not an approved addiction treatment in the United States.
What it may feel like: The acute phase may be less like a colorful recreational trip and more like being pinned inside a lucid waking dream: buzzing, rapid autobiographical scenes, vomiting, severe imbalance, and hours of reviewing memories while the body is difficult to operate. Some opioid-dependent users report withdrawal and craving switching off with astonishing speed. Others endure terror, insomnia, arrhythmia, prolonged unreality, or no durable recovery.
The simplest description: Ibogaine may interrupt withdrawal long enough to expose a new behavioral path, but it does so while placing the heart and nervous system under a risk that cannot be judged by how calm the experience feels.
How It Works
Ibogaine and noribogaine engage multiple systems, including serotonin transporters/receptors, NMDA, nicotinic, opioid, sigma, and neurotrophic signaling. No single mechanism explains withdrawal suppression. Ibogaine and noribogaine block cardiac hERG potassium channels, delaying repolarization and prolonging QT—an electrical setup for torsades and sudden death.
CYP2D6 genotype and inhibitors can shift parent/metabolite exposure more than tenfold. Noribogaine persists far longer than ibogaine, so cardiac and drug-interaction risk can continue after the visions end.
Dose and How It Was Studied
A controlled healthy-volunteer PK study used 20 mg oral ibogaine; observational detoxification protocols have used far higher weight-based exposures. Those detox doses are not recommendations and have produced severe ataxia, bradycardia, QT prolongation, and deaths. This is not a home-detox compound.
Ibogaine hydrochloride is the more defined oral research form; total-alkaloid extracts and root bark have variable ibogaine and co-alkaloid content. Food, vomiting, extract composition, and CYP2D6 status change exposure. No solubility trick makes nonmedical dosing safe.
Timing and Pharmacokinetics
- Subjective onset: Commonly one to three hours orally.
- Pharmacologic onset / Tmax: Parent ibogaine Tmax is often around 1.5–2 hours; noribogaine peaks later.
- Absorption/bioavailability: Oral absorption is substantial but highly variable because of first-pass CYP2D6 metabolism.
- Full practical effect: The visionary/ataxic phase develops over several hours; withdrawal suppression may appear during that phase.
- Subjective duration: Acute effects commonly occupy 12–24 hours, followed by prolonged stimulation, sleeplessness, or an after-effect lasting days.
- Half-life: Ibogaine roughly 1–10 hours depending on CYP2D6 status; noribogaine about 28–49 hours.
- Accumulation/steady state: A flood dose is not steady-state use. Long-lived noribogaine creates meaningful multi-day exposure after one administration.
- Near-complete elimination: Parent may require roughly one to two days; noribogaine may require six to ten days by five half-lives.
- Metabolism/elimination: CYP2D6 O-demethylation forms noribogaine, followed by glucuronidation and renal/biliary elimination.
Evidence and Experiences
Observational and small clinical studies report rapid reductions in opioid withdrawal and craving, but controlled efficacy evidence is weak and cannot match the certainty of approved treatments such as buprenorphine and methadone. A treatment that sometimes works dramatically can still have an unfavorable mortality profile.
Experience reports include visions, buzzing, purging, profound autobiographical review, severe ataxia, interrupted withdrawal, and months of recovery; they also include terrifying suicidal imagery, persistent derealization, and medical emergencies. Ataxia and difficult-experience discussion · Long-term negative report
Safety, Interactions, and Monitoring
Ibogaine can cause QT prolongation, bradycardia, torsades, cardiac arrest, seizure, severe ataxia, vomiting/aspiration, electrolyte abnormalities, and death. Emergency evaluation is required for fainting, palpitations, chest pain, seizure, breathing difficulty, persistent vomiting, severe confusion, or suicidality.
It must not be combined casually with methadone or other QT-prolonging drugs, CYP2D6 inhibitors, antidepressants, antipsychotics, stimulants, antiemetics, antibiotics, or electrolyte-depleting substances. Opioid, alcohol, benzodiazepine, or stimulant withdrawal creates additional medical risk. Clinical screening requires ECG/QTc, electrolytes, liver/kidney assessment, medication review, continuous cardiac monitoring, resuscitation capacity, and trained medical staff. Dependence is not typical, and tolerance/cycling rules are not established; repetition before noribogaine clears can accumulate risk. Product-quality testing must distinguish HCl from extracts and measure alkaloids/adulterants.
Bottom Line
Ibogaine is one of the few compounds whose anecdotal effect on opioid withdrawal is dramatic enough to be scientifically compelling—and whose cardiac danger is dramatic enough to make nonmedical use indefensible. The monitoring infrastructure is part of the intervention.
25.7 Non-Hallucinogenic Psychoplastogens
25.7.1 Tabernanthalog / TBG / DLX-007 — An Iboga-Inspired Psychoplastogen With Preliminary Human Reports
What it is: Tabernanthalog (TBG; DLX-007) is a simplified iboga-inspired psychoplastogen engineered to retain plasticity and anti-addiction-like effects in animals while reducing hallucination and cardiac liabilities. It is not ibogaine, tabernanthine, or an approved medicine.
What it may feel like: Human phenomenology is preliminary, but it is not absent. Arthur Juliani reported that ordinary vision remained visually normal while attention changed dramatically: wherever he looked felt like a perfectly framed photograph, spontaneous thoughts became quieter, and he could sit with difficult thoughts and emotions with almost supernatural patience and equanimity. He described onset around 45 minutes, effects lasting about nine hours, stomach discomfort, a later headache, and a mild next-day afterglow.
A broader collection of at least a dozen claimed users partially converges on a calm, introspective, unusually open state: greater interest in ordinary surroundings, mental quiet, empathy, emotional processing, or a “Zen” body high with few visuals. The reports also reveal a less flattering side—nausea, dizziness, gastrointestinal distress, bed-lock, anxiety, and at higher exposures a clearly altered, dissociative- or psychedelic-like state that may last much of the day. These reports do not establish incidence, purity, or safety, but they provide a real starting map of what TBG may feel like. Arthur Juliani’s phenomenological report · Psychedelic Alpha’s report collection
The simplest description: TBG may preserve one narrow but important part of a psychedelic state—the way attention becomes patient, significant, open, and capable of sitting with difficult material—without necessarily producing the normal visual and reality-replacing trip. The reports suggest that separation is incomplete and strongly exposure-dependent.
How It Works
Preclinical work suggests serotonergic signaling—especially 5-HT2A-related pathways—followed by dendritic growth and other plasticity markers. Rodent studies report reduced drug-seeking and antidepressant-like behavior without a classic head-twitch response. Animal psychoplastogenicity does not establish human efficacy, non-hallucinogenicity, or cardiac safety.
Dose and How It Was Studied
There is no validated human dose and, as of early 2026, no published human clinical trial. Animal milligrams-per-kilogram cannot be converted into a self-experiment schedule. Consumer water/lipid solubility, pH behavior, oral formulation, food effect, and route are not established.
Timing and Pharmacokinetics
The efficacy evidence remains preclinical. Rodent models of depression, alcohol seeking, and heroin seeking are useful for drug discovery but do not establish treatment of human addiction or mood disorders.
The phenomenological evidence is a different evidence stream. One unusually detailed self-experiment and a collection of at least a dozen claimed users suggest that TBG is often psychoactive despite its “non-hallucinogenic” design. Several reports converge on equanimity, enhanced significance, empathy, open-mindedness, introspection, and few visuals at lower or moderate exposures; others describe no useful effect, craving reduction without broader withdrawal relief, or overt psychedelic and dissociative effects at higher exposure. Product identity was not independently established in most cases, conflicts of interest are possible, and self-selection is extreme. Those limitations lower confidence without reducing the reports to zero information.
Safety, Interactions, and Monitoring
Human adverse-event incidence, QT effects, organ toxicity, reproductive risk, interactions, tolerance, dependence, withdrawal, and cycling requirements are unknown. The design goal of reduced hERG activity is not proof of human cardiac safety, and rodent head-twitch results did not predict the full range of claimed human psychoactivity. Reported nausea, vomiting, diarrhea, dizziness, anxiety, sedation, bed-lock, headache, and prolonged alteration belong in the practical risk picture. Do not combine an uncharacterized research compound with serotonergic drugs, MAO inhibitors, stimulants, psychedelics, or addiction treatments.
Pregnancy/breastfeeding, minors, cardiovascular disease, seizure history, bipolar disorder, psychosis, and serious organ disease have no safe self-use basis. Product-quality testing would need identity, assay, stereochemistry, impurities, residual solvents, and contaminants; even perfect chemical verification would not supply missing human toxicology.
Bottom Line
TBG is scientifically interesting precisely because it attempts to separate iboga-like plasticity and therapeutic attention from hallucination and cardiac toxicity. The available reports suggest that it may partly succeed: equanimity and introspection can appear without conventional visuals, although higher exposures may become unmistakably psychoactive and physically unpleasant. That preliminary human signal deserves to be described rather than erased, while the missing human PK, verified dosing, toxicology, and product chain still prevent a defensible practical protocol.
What it is: Tabernanthalog (TBG; DLX-007) is a simplified iboga-inspired psychoplastogen engineered to retain plasticity and anti-addiction-like effects in animals while reducing hallucination and cardiac liabilities. It is not ibogaine, tabernanthine, or an approved medicine.
What it may feel like: Human phenomenology is preliminary, but it is not absent. Arthur Juliani reported that ordinary vision remained visually normal while attention changed dramatically: wherever he looked felt like a perfectly framed photograph, spontaneous thoughts became quieter, and he could sit with difficult thoughts and emotions with almost supernatural patience and equanimity. He described onset around 45 minutes, effects lasting about nine hours, stomach discomfort, a later headache, and a mild next-day afterglow.
A broader collection of at least a dozen claimed users partially converges on a calm, introspective, unusually open state: greater interest in ordinary surroundings, mental quiet, empathy, emotional processing, or a “Zen” body high with few visuals. The reports also reveal a less flattering side—nausea, dizziness, gastrointestinal distress, bed-lock, anxiety, and at higher exposures a clearly altered, dissociative- or psychedelic-like state that may last much of the day. These reports do not establish incidence, purity, or safety, but they provide a real starting map of what TBG may feel like. Arthur Juliani’s phenomenological report · Psychedelic Alpha’s report collection
The simplest description: TBG may preserve one narrow but important part of a psychedelic state—the way attention becomes patient, significant, open, and capable of sitting with difficult material—without necessarily producing the normal visual and reality-replacing trip. The reports suggest that separation is incomplete and strongly exposure-dependent.
How It Works
Preclinical work suggests serotonergic signaling—especially 5-HT2A-related pathways—followed by dendritic growth and other plasticity markers. Rodent studies report reduced drug-seeking and antidepressant-like behavior without a classic head-twitch response. Animal psychoplastogenicity does not establish human efficacy, non-hallucinogenicity, or cardiac safety.
Dose and How It Was Studied
There is no validated human dose and, as of early 2026, no published human clinical trial. Animal milligrams-per-kilogram cannot be converted into a self-experiment schedule. Consumer water/lipid solubility, pH behavior, oral formulation, food effect, and route are not established.
Timing and Pharmacokinetics
- Subjective onset: Preliminary reports range from approximately 15–45 minutes, but products and exposures were not clinically verified.
- Pharmacologic onset / Tmax: Unknown in humans.
- Absorption/bioavailability: Unknown in humans.
- Full practical effect: Reports suggest a same-day altered attentional state rather than an effect that can be understood from plasma timing alone.
- Subjective duration: Roughly nine to eleven hours recurs in moderate-exposure reports; a much higher-exposure report described approximately twenty hours. These are anecdotes, not validated PK.
- Half-life: Unknown in humans.
- Accumulation/steady state: Cannot be calculated.
- Near-complete elimination: Cannot be calculated.
- Metabolism/elimination: Unknown in humans.
The efficacy evidence remains preclinical. Rodent models of depression, alcohol seeking, and heroin seeking are useful for drug discovery but do not establish treatment of human addiction or mood disorders.
The phenomenological evidence is a different evidence stream. One unusually detailed self-experiment and a collection of at least a dozen claimed users suggest that TBG is often psychoactive despite its “non-hallucinogenic” design. Several reports converge on equanimity, enhanced significance, empathy, open-mindedness, introspection, and few visuals at lower or moderate exposures; others describe no useful effect, craving reduction without broader withdrawal relief, or overt psychedelic and dissociative effects at higher exposure. Product identity was not independently established in most cases, conflicts of interest are possible, and self-selection is extreme. Those limitations lower confidence without reducing the reports to zero information.
Safety, Interactions, and Monitoring
Human adverse-event incidence, QT effects, organ toxicity, reproductive risk, interactions, tolerance, dependence, withdrawal, and cycling requirements are unknown. The design goal of reduced hERG activity is not proof of human cardiac safety, and rodent head-twitch results did not predict the full range of claimed human psychoactivity. Reported nausea, vomiting, diarrhea, dizziness, anxiety, sedation, bed-lock, headache, and prolonged alteration belong in the practical risk picture. Do not combine an uncharacterized research compound with serotonergic drugs, MAO inhibitors, stimulants, psychedelics, or addiction treatments.
Pregnancy/breastfeeding, minors, cardiovascular disease, seizure history, bipolar disorder, psychosis, and serious organ disease have no safe self-use basis. Product-quality testing would need identity, assay, stereochemistry, impurities, residual solvents, and contaminants; even perfect chemical verification would not supply missing human toxicology.
Bottom Line
TBG is scientifically interesting precisely because it attempts to separate iboga-like plasticity and therapeutic attention from hallucination and cardiac toxicity. The available reports suggest that it may partly succeed: equanimity and introspection can appear without conventional visuals, although higher exposures may become unmistakably psychoactive and physically unpleasant. That preliminary human signal deserves to be described rather than erased, while the missing human PK, verified dosing, toxicology, and product chain still prevent a defensible practical protocol.
25.8 Microdosing
Microdosing means repeated exposure intended to remain sub-perceptual or only minimally perceptual. The proposed image is attractive: preserve flexibility, energy, and creativity while removing the destabilizing trip. The measurement problem is that the desired effects are subtle enough for expectation, daily mood variation, caffeine, sleep, and selective memory to imitate them. If a user can reliably identify the active day, blinding can also collapse.
Controlled evidence does not currently support a reliable general cognitive upgrade. A 2026 meta-analysis found no detectable benefit across most cognitive domains and a small reduction in cognitive control, while other reviews emphasize that the evidence base remains small and heterogeneous. Repeated low exposure also leaves unresolved questions about sleep, anxiety, cardiovascular signaling, 5-HT2B-related long-term risk, tolerance, and mood destabilization. A microdose is a lower exposure, not a different law of pharmacology.
25.9 Set, Setting, and Integration
Set is the person's mental state, expectations, motives, and unresolved vulnerabilities. Setting is the physical and social environment. Integration means testing what happened against reality and converting the genuinely useful parts into behavior. These are not decorative additions to the drug; they are variables that determine what a temporarily plastic brain is learning.
An insight should survive ordinary daylight. Write it down, wait until sleep and baseline judgment return, ask what evidence would disprove it, and look for a specific behavior that improves. Emotional force is not a truth detector, and a sense of cosmic certainty is itself one of the drug effects.
25.10 Psychedelic Monitoring
The clinical model tracks far more than whether the experience felt profound: exact formulation, route, vital signs, panic, orientation, motor safety, sleep, medication interactions, suicidality, mania, persistent perceptual change, and days-to-weeks function. Cognitive change should be judged by durable accuracy, flexibility, relationships, and behavior—not by novelty or intensity.
Chapter 26 — GABAergic and Relaxation Compounds
GABA is the brain's principal inhibitory transmitter: it lowers the probability that neurons will fire and keeps excitation organized. Inhibition is necessary for attention, sleep, and motor control, but broadly increasing it can exchange anxiety for weak memory encoding, slowed reaction, poor coordination, and impaired judgment.
Imagine excitation and inhibition as the accelerator and brake of a racing car. Removing the brake does not make the driver faster; it makes the car uncontrollable. Holding the brake down continuously does not make the driver calmer; it prevents the car from moving. Useful regulation keeps the system inside the narrow range where irrelevant activity is suppressed without disabling the activity required for memory and thought.
26.1 The GABA System
GABA is synthesized from glutamate by glutamic-acid decarboxylase, using vitamin-B6-related chemistry. After release, transporters clear it and neurons or astrocytes recycle it. GABA-A receptors are ligand-gated chloride channels that produce rapid inhibition. GABA-B receptors are slower G-protein-coupled receptors that reduce calcium entry, increase potassium conductance, and suppress transmitter release.
Receptor subtype and location determine the result. GABA-A receptors containing different alpha subunits contribute differently to sedation, anxiety reduction, amnesia, motor impairment, and anticonvulsant action. “GABAergic” therefore says almost nothing about whether a compound is mild, useful, impairing, addictive, or medically dangerous.
26.2 Major GABAergic and Inhibitory Classes
- GABA-A positive allosteric modulators: benzodiazepines, Z-drugs, barbiturates, alcohol, and some botanical constituents.
- GABA-B agonists: baclofen and phenibut.
- Alpha2delta calcium-channel ligands: gabapentin and pregabalin, which are not direct GABA agonists despite their names.
- Lower-intensity multi-target compounds: L-theanine and kava.
26.3 Broad GABA-A Positive Allosteric Modulators
26.3.1 Benzodiazepines — Fast Relief That Can Quiet Anxiety and Memory at the Same Time
What it is: Benzodiazepines are prescription positive allosteric modulators of GABA-A receptors. Alprazolam, lorazepam, diazepam, clonazepam, and midazolam differ dramatically in onset, half-life, active metabolites, and approved use; “a benzo” is not one drug.
What it may feel like: Panic can collapse into quiet: the chest unclenches, social threat loses urgency, and sleep seems possible. The same person may become slow, emotionally padded, disinhibited, falsely confident, or unable to remember a conversation. With repetition, the relief may shorten until baseline feels worse between doses and the drug feels less like a benefit than permission to feel normal.
The simplest description: Benzodiazepines strengthen the brain’s braking system. The brake can stop a panic spiral or seizure, but it also slows memory encoding, reaction, coordination, and error detection.
How It Works
They bind the benzodiazepine site on susceptible GABA-A receptors and increase the frequency of GABA-triggered chloride-channel opening. Subunit distribution helps separate anxiolysis, sedation, amnesia, anticonvulsant action, and muscle relaxation, but no common benzodiazepine selectively removes anxiety while guaranteeing intact judgment.
Dose and How It Was Studied
There is no class-wide dose. Dosing belongs to a specific molecule, formulation, diagnosis, organ function, age, and duration under a prescriber. Tablets, liquids, orally disintegrating forms, extended release, and medical IV preparations are not interchangeable.
Solubility varies: some agents are lipophilic and oxidatively metabolized, while lorazepam/oxazepam/temazepam rely more on glucuronidation. Use only the prescribed product as labeled. Food effects vary and fasting is not a general optimization.
Timing and Pharmacokinetics
Large clinical evidence supports selected short-term uses in panic, seizures, procedures, and insomnia. The same evidence establishes impaired memory and psychomotor performance—not nootropic action. Feeling calmer may improve performance when pathological anxiety is the bottleneck, but it does not mean the drug enhanced a healthy brain.
Recovery forums vividly describe the arc from “I finally felt normal” to missing memories, escalating use, interdose anxiety, tinnitus, insomnia, cognitive fog, and months-long recovery. These reports overrepresent difficult cases but accurately illustrate why dependence is not synonymous with misuse. FDA boxed-warning update · Memory and rebound experiences
Safety, Interactions, and Monitoring
Sedation, falls, ataxia, impaired driving, amnesia, paradoxical agitation, and respiratory depression—especially in combinations—are central risks. Opioids, alcohol, Z-drugs, barbiturates, gabapentinoids, sedating antihistamines, and muscle relaxants can produce nonlinear respiratory depression, coma, aspiration, or death.
Do not stop regular use abruptly. Tolerance and physical dependence can develop; withdrawal can cause panic, delirium, hallucinations, seizures, and death, so tapering belongs with a clinician. FDA requires warnings for abuse, misuse, addiction, physical dependence, and withdrawal. Sleep apnea/respiratory disease, pregnancy, older age/falls, substance-use vulnerability, and serious liver/kidney disease require review. Product quality means a regulated prescription—counterfeit “Xanax” may contain fentanyl or designer benzodiazepines. Track exact product/time, alertness, breathing, balance, memory, sleep, dose creep, interdose symptoms, and next-day function.
Bottom Line
Benzodiazepines can be excellent medicines when the target justifies the brake. As cognitive enhancers they fail by mechanism: the calm can be real while memory, judgment, and dependence risk quietly worsen.
What it is: Benzodiazepines are prescription positive allosteric modulators of GABA-A receptors. Alprazolam, lorazepam, diazepam, clonazepam, and midazolam differ dramatically in onset, half-life, active metabolites, and approved use; “a benzo” is not one drug.
What it may feel like: Panic can collapse into quiet: the chest unclenches, social threat loses urgency, and sleep seems possible. The same person may become slow, emotionally padded, disinhibited, falsely confident, or unable to remember a conversation. With repetition, the relief may shorten until baseline feels worse between doses and the drug feels less like a benefit than permission to feel normal.
The simplest description: Benzodiazepines strengthen the brain’s braking system. The brake can stop a panic spiral or seizure, but it also slows memory encoding, reaction, coordination, and error detection.
How It Works
They bind the benzodiazepine site on susceptible GABA-A receptors and increase the frequency of GABA-triggered chloride-channel opening. Subunit distribution helps separate anxiolysis, sedation, amnesia, anticonvulsant action, and muscle relaxation, but no common benzodiazepine selectively removes anxiety while guaranteeing intact judgment.
Dose and How It Was Studied
There is no class-wide dose. Dosing belongs to a specific molecule, formulation, diagnosis, organ function, age, and duration under a prescriber. Tablets, liquids, orally disintegrating forms, extended release, and medical IV preparations are not interchangeable.
Solubility varies: some agents are lipophilic and oxidatively metabolized, while lorazepam/oxazepam/temazepam rely more on glucuronidation. Use only the prescribed product as labeled. Food effects vary and fasting is not a general optimization.
Timing and Pharmacokinetics
- Subjective onset: Common oral agents may be felt in 15–60 minutes, but formulation and molecule dominate.
- Pharmacologic onset / Tmax: Roughly 0.5–3 hours orally across common drugs; medical IV use is much faster.
- Absorption/bioavailability: Most are well absorbed, with molecule-specific first-pass effects.
- Full practical effect: Often near Tmax; sedation and amnesia may deepen after anxiety first improves.
- Subjective duration: From several hours to the next day or longer.
- Half-life: Approximately hours to several days, including active metabolites.
- Accumulation/steady state: Short agents can produce interdose rebound; long agents/metabolites may accumulate over days to weeks.
- Near-complete elimination: From roughly a day to multiple weeks depending on agent, metabolites, age, and liver function.
- Metabolism/elimination: Many use CYP3A4/2C19 oxidation; “LOT” agents undergo glucuronidation; metabolites are mainly renally excreted.
Large clinical evidence supports selected short-term uses in panic, seizures, procedures, and insomnia. The same evidence establishes impaired memory and psychomotor performance—not nootropic action. Feeling calmer may improve performance when pathological anxiety is the bottleneck, but it does not mean the drug enhanced a healthy brain.
Recovery forums vividly describe the arc from “I finally felt normal” to missing memories, escalating use, interdose anxiety, tinnitus, insomnia, cognitive fog, and months-long recovery. These reports overrepresent difficult cases but accurately illustrate why dependence is not synonymous with misuse. FDA boxed-warning update · Memory and rebound experiences
Safety, Interactions, and Monitoring
Sedation, falls, ataxia, impaired driving, amnesia, paradoxical agitation, and respiratory depression—especially in combinations—are central risks. Opioids, alcohol, Z-drugs, barbiturates, gabapentinoids, sedating antihistamines, and muscle relaxants can produce nonlinear respiratory depression, coma, aspiration, or death.
Do not stop regular use abruptly. Tolerance and physical dependence can develop; withdrawal can cause panic, delirium, hallucinations, seizures, and death, so tapering belongs with a clinician. FDA requires warnings for abuse, misuse, addiction, physical dependence, and withdrawal. Sleep apnea/respiratory disease, pregnancy, older age/falls, substance-use vulnerability, and serious liver/kidney disease require review. Product quality means a regulated prescription—counterfeit “Xanax” may contain fentanyl or designer benzodiazepines. Track exact product/time, alertness, breathing, balance, memory, sleep, dose creep, interdose symptoms, and next-day function.
Bottom Line
Benzodiazepines can be excellent medicines when the target justifies the brake. As cognitive enhancers they fail by mechanism: the calm can be real while memory, judgment, and dependence risk quietly worsen.
26.3.2 Barbiturates — Older GABAergic Brakes With a Narrower Distance Between Sleep and Death
What it is: Barbiturates are barbituric-acid-derived sedative, anesthetic, and antiseizure drugs. Phenobarbital is long acting; shorter anesthetic agents behave differently. They have a substantially narrower therapeutic margin than benzodiazepines.
What it may feel like: Anxiety and wakefulness can give way to heavy warmth, slowed thought, poor coordination, disinhibition, and memory gaps. At higher exposure, the transition is not toward more insight but toward stupor, loss of airway protection, coma, and respiratory arrest.
The simplest description: Barbiturates lengthen the brain’s inhibitory signal and can push it farther than benzodiazepines; the same dose-response curve contains calm, anesthesia, and fatal respiratory depression.
How It Works
Barbiturates positively modulate GABA-A receptors by prolonging chloride-channel opening and, at high concentrations, can directly activate the channel and suppress excitatory glutamate signaling. This weaker dependence on endogenous GABA helps explain their overdose danger.
Dose and How It Was Studied
There is no class-wide nootropic or relaxation dose. Phenobarbital dosing is prescription-only and individualized for seizure or withdrawal medicine; anesthetic barbiturates are administered medically. Solubility varies by molecule and salt—phenobarbital is only slightly water soluble while sodium salts differ. Never improvise formulation or substitute salts.
Timing and Pharmacokinetics
Evidence and Experiences
Clinical evidence supports specific seizure, anesthesia, and medically supervised withdrawal uses. It also documents sedation, cognitive impairment, enzyme interactions, overdose, dependence, and dangerous withdrawal. There is no healthy cognitive-enhancement case.
Modern forum experience is dominated by medical phenobarbital or polysubstance use rather than clean enhancement reports. Subjective calm is a poor safety gauge because respiratory depression and accumulation can progress while the user feels merely sleepy.
Safety, Interactions, and Monitoring
Respiratory depression, hypotension, coma, falls, aspiration, severe skin reactions, cognitive impairment, dependence, and fatal overdose are central risks. Alcohol, opioids, benzodiazepines, Z-drugs, gabapentinoids, sedating antihistamines, and anesthetics markedly increase danger.
Tolerance and physical dependence can develop; abrupt withdrawal after dependence can cause delirium, seizures, and death. Enzyme induction can reduce concentrations of oral contraceptives, anticoagulants, doxycycline, steroids, and many other medicines, with effects persisting after discontinuation. Pregnancy, porphyria, respiratory disease, liver/kidney disease, older age, and substance-use vulnerability require specialist management. Product-quality means regulated prescription or hospital formulation only. Monitor serum levels when indicated, respiration, BP, alertness, coordination, rash, medication interactions, cognition, and dose accumulation.
Bottom Line
Barbiturates remain useful medicines in narrow contexts, not general calming compounds. Their long accumulation, enzyme induction, dependence, and short distance from sedation to lethal respiratory depression make the nootropic risk-benefit unequivocally negative.
What it is: Barbiturates are barbituric-acid-derived sedative, anesthetic, and antiseizure drugs. Phenobarbital is long acting; shorter anesthetic agents behave differently. They have a substantially narrower therapeutic margin than benzodiazepines.
What it may feel like: Anxiety and wakefulness can give way to heavy warmth, slowed thought, poor coordination, disinhibition, and memory gaps. At higher exposure, the transition is not toward more insight but toward stupor, loss of airway protection, coma, and respiratory arrest.
The simplest description: Barbiturates lengthen the brain’s inhibitory signal and can push it farther than benzodiazepines; the same dose-response curve contains calm, anesthesia, and fatal respiratory depression.
How It Works
Barbiturates positively modulate GABA-A receptors by prolonging chloride-channel opening and, at high concentrations, can directly activate the channel and suppress excitatory glutamate signaling. This weaker dependence on endogenous GABA helps explain their overdose danger.
Dose and How It Was Studied
There is no class-wide nootropic or relaxation dose. Phenobarbital dosing is prescription-only and individualized for seizure or withdrawal medicine; anesthetic barbiturates are administered medically. Solubility varies by molecule and salt—phenobarbital is only slightly water soluble while sodium salts differ. Never improvise formulation or substitute salts.
Timing and Pharmacokinetics
- Subjective onset: Oral phenobarbital may begin within 30–60 minutes; IV anesthetics act within seconds.
- Pharmacologic onset / Tmax: Oral Tmax is molecule/formulation dependent and often several hours for phenobarbital.
- Absorption/bioavailability: Oral absorption is generally substantial; sodium solutions and fasting can speed absorption.
- Full practical effect: Sedation may deepen after the first subjective change.
- Subjective duration: Hours to multiple days for long-acting agents.
- Half-life: Phenobarbital averages about 79 hours in adults, with a labeled range of 53–118 hours; other barbiturates are much shorter.
- Accumulation/steady state: Phenobarbital takes roughly two to three weeks to approach steady state and accumulates strongly.
- Near-complete elimination: Phenobarbital can require approximately 11–25 days by five half-lives.
- Metabolism/elimination: Hepatic metabolism plus renal excretion; phenobarbital induces drug-metabolizing enzymes and some unchanged drug is renally cleared.
Evidence and Experiences
Clinical evidence supports specific seizure, anesthesia, and medically supervised withdrawal uses. It also documents sedation, cognitive impairment, enzyme interactions, overdose, dependence, and dangerous withdrawal. There is no healthy cognitive-enhancement case.
Modern forum experience is dominated by medical phenobarbital or polysubstance use rather than clean enhancement reports. Subjective calm is a poor safety gauge because respiratory depression and accumulation can progress while the user feels merely sleepy.
Safety, Interactions, and Monitoring
Respiratory depression, hypotension, coma, falls, aspiration, severe skin reactions, cognitive impairment, dependence, and fatal overdose are central risks. Alcohol, opioids, benzodiazepines, Z-drugs, gabapentinoids, sedating antihistamines, and anesthetics markedly increase danger.
Tolerance and physical dependence can develop; abrupt withdrawal after dependence can cause delirium, seizures, and death. Enzyme induction can reduce concentrations of oral contraceptives, anticoagulants, doxycycline, steroids, and many other medicines, with effects persisting after discontinuation. Pregnancy, porphyria, respiratory disease, liver/kidney disease, older age, and substance-use vulnerability require specialist management. Product-quality means regulated prescription or hospital formulation only. Monitor serum levels when indicated, respiration, BP, alertness, coordination, rash, medication interactions, cognition, and dose accumulation.
Bottom Line
Barbiturates remain useful medicines in narrow contexts, not general calming compounds. Their long accumulation, enzyme induction, dependence, and short distance from sedation to lethal respiratory depression make the nootropic risk-benefit unequivocally negative.
26.3.3 Alcohol / Ethanol — Social Disinhibition That Feels Like Added Ability While Removing It
What it is: Ethanol is a small, water- and lipid-compatible psychoactive molecule distributed through total body water. It affects GABA-A, NMDA, glycine, ion channels, dopamine, and membrane signaling rather than acting at one clean target.
What it may feel like: Self-monitoring relaxes first: conversation seems easier, jokes feel better, threat recedes, and confidence rises. The trap is that error detection, reaction, memory encoding, and judgment deteriorate during the same window, so the user can feel more socially capable while becoming objectively less accurate. Later come sedation, fragmented sleep, dehydration, anxiety, and a cognitively expensive next day.
The simplest description: Alcohol turns down the inner critic before it turns down the performance. The subjective gain is often the loss of awareness that performance is declining.
How It Works
Ethanol enhances inhibitory signaling and suppresses excitatory NMDA-related signaling while altering reward and stress circuits. It crosses the BBB freely and affects every organ. Acute disinhibition, sedation, amnesia, and motor impairment are points on the same exposure curve.
Dose and How It Was Studied
There is no nootropic dose. “One drink” is a standardized ethanol quantity, not a glass size, and real pours vary. Concentration, drinking speed, food, sex-related body-water distribution, medications, liver function, and genetics determine blood alcohol concentration (BAC).
Ethanol mixes with water and lipids and is absorbed from stomach and small intestine. Food—especially a substantial meal—slows absorption and lowers the peak, while carbonated concentrated drinks may raise it faster. Slower absorption reduces the peak but does not cancel total ethanol toxicity.
Solubility and practical administration: Ethanol is completely miscible with water and readily crosses biological membranes; it does not require fat for absorption. Food slows gastric emptying and usually lowers and delays the peak, whereas an empty stomach makes the rise faster and less predictable. Dilution changes irritation and drinking speed, not the total ethanol dose.
Timing and Pharmacokinetics
Evidence and Experiences
Controlled evidence consistently shows dose-dependent impairment of reaction, divided attention, memory, inhibition, and sleep architecture. Lower social anxiety can improve willingness to speak, but willingness is not enhanced cognition. Population evidence links chronic and binge exposure to addiction, injuries, liver/heart disease, cancers, and brain harm.
Experience reports often call alcohol a social lubricant because awkwardness becomes less salient. Blackouts demonstrate the extreme version: a person can converse and act while failing to form retrievable memories. Next-day “hangxiety” combines sleep fragmentation, autonomic rebound, inflammation, dehydration, and consequences of impaired decisions.
Safety, Interactions, and Monitoring
Acute risks include poisoning, vomiting/aspiration, respiratory depression, injury, violence, risky sex, hypoglycemia, and impaired driving. Breathing difficulty, inability to awaken, seizure, blue/pale skin, repeated vomiting, confusion, or hypothermia requires emergency help; do not leave an unconscious person alone.
Opioids, benzodiazepines, barbiturates, Z-drugs, gabapentinoids, sedating antihistamines, and muscle relaxants can make respiratory depression nonlinear and fatal. Metronidazole-like interactions, diabetes medicines, anticoagulants, liver disease, pregnancy, adolescence, seizure risk, and psychiatric instability require additional caution. Tolerance, dependence, withdrawal seizures/delirium, and compulsive use are established; abrupt cessation after heavy dependence can be medically dangerous. Product-quality risks include counterfeit alcohol and methanol. Track actual standard drinks, timing, blackouts, sleep, cravings, tolerance, withdrawal, mood, BP, and consequences—not perceived “handling.”
Bottom Line
Alcohol can make social behavior feel easier because it disables the monitor that notices mistakes. As a nootropic it is almost perfectly inverted: confidence rises while memory, judgment, sleep, and reaction fall.
What it is: Ethanol is a small, water- and lipid-compatible psychoactive molecule distributed through total body water. It affects GABA-A, NMDA, glycine, ion channels, dopamine, and membrane signaling rather than acting at one clean target.
What it may feel like: Self-monitoring relaxes first: conversation seems easier, jokes feel better, threat recedes, and confidence rises. The trap is that error detection, reaction, memory encoding, and judgment deteriorate during the same window, so the user can feel more socially capable while becoming objectively less accurate. Later come sedation, fragmented sleep, dehydration, anxiety, and a cognitively expensive next day.
The simplest description: Alcohol turns down the inner critic before it turns down the performance. The subjective gain is often the loss of awareness that performance is declining.
How It Works
Ethanol enhances inhibitory signaling and suppresses excitatory NMDA-related signaling while altering reward and stress circuits. It crosses the BBB freely and affects every organ. Acute disinhibition, sedation, amnesia, and motor impairment are points on the same exposure curve.
Dose and How It Was Studied
There is no nootropic dose. “One drink” is a standardized ethanol quantity, not a glass size, and real pours vary. Concentration, drinking speed, food, sex-related body-water distribution, medications, liver function, and genetics determine blood alcohol concentration (BAC).
Ethanol mixes with water and lipids and is absorbed from stomach and small intestine. Food—especially a substantial meal—slows absorption and lowers the peak, while carbonated concentrated drinks may raise it faster. Slower absorption reduces the peak but does not cancel total ethanol toxicity.
Solubility and practical administration: Ethanol is completely miscible with water and readily crosses biological membranes; it does not require fat for absorption. Food slows gastric emptying and usually lowers and delays the peak, whereas an empty stomach makes the rise faster and less predictable. Dilution changes irritation and drinking speed, not the total ethanol dose.
Timing and Pharmacokinetics
- Subjective onset: Commonly 10–30 minutes, faster on an empty stomach.
- Pharmacologic onset / Tmax: Peak BAC often occurs around 30–90 minutes, but can be later with food.
- Absorption/bioavailability: Rapid, high oral absorption with variable first-pass metabolism.
- Full practical effect: Disinhibition may precede obvious motor impairment; the peak can continue rising after the last drink.
- Subjective duration: Several hours, followed by sleep disruption and next-day effects.
- Half-life: Ethanol follows near zero-order elimination over common concentrations, so a single half-life is misleading.
- Accumulation/steady state: Drinking faster than metabolic clearance causes accumulation; chronic use produces metabolic and pharmacodynamic tolerance.
- Near-complete elimination: Depends on total ethanol and individual clearance; time—not coffee, cold showers, or exercise—removes it.
- Metabolism/elimination: Alcohol dehydrogenase forms toxic acetaldehyde; aldehyde dehydrogenase forms acetate. CYP2E1 and catalase also contribute.
Evidence and Experiences
Controlled evidence consistently shows dose-dependent impairment of reaction, divided attention, memory, inhibition, and sleep architecture. Lower social anxiety can improve willingness to speak, but willingness is not enhanced cognition. Population evidence links chronic and binge exposure to addiction, injuries, liver/heart disease, cancers, and brain harm.
Experience reports often call alcohol a social lubricant because awkwardness becomes less salient. Blackouts demonstrate the extreme version: a person can converse and act while failing to form retrievable memories. Next-day “hangxiety” combines sleep fragmentation, autonomic rebound, inflammation, dehydration, and consequences of impaired decisions.
Safety, Interactions, and Monitoring
Acute risks include poisoning, vomiting/aspiration, respiratory depression, injury, violence, risky sex, hypoglycemia, and impaired driving. Breathing difficulty, inability to awaken, seizure, blue/pale skin, repeated vomiting, confusion, or hypothermia requires emergency help; do not leave an unconscious person alone.
Opioids, benzodiazepines, barbiturates, Z-drugs, gabapentinoids, sedating antihistamines, and muscle relaxants can make respiratory depression nonlinear and fatal. Metronidazole-like interactions, diabetes medicines, anticoagulants, liver disease, pregnancy, adolescence, seizure risk, and psychiatric instability require additional caution. Tolerance, dependence, withdrawal seizures/delirium, and compulsive use are established; abrupt cessation after heavy dependence can be medically dangerous. Product-quality risks include counterfeit alcohol and methanol. Track actual standard drinks, timing, blackouts, sleep, cravings, tolerance, withdrawal, mood, BP, and consequences—not perceived “handling.”
Bottom Line
Alcohol can make social behavior feel easier because it disables the monitor that notices mistakes. As a nootropic it is almost perfectly inverted: confidence rises while memory, judgment, sleep, and reaction fall.
26.4 GABA-B Agonists
GABA-B receptors operate more slowly than GABA-A channels. Their activation suppresses transmitter release and motor excitability through calcium and potassium signaling. This can reduce spasticity or social fear, but delayed onset, bodily weakness, tolerance, and severe withdrawal make the class fundamentally different from a mild calming supplement.
26.4.1 Phenibut / β-Phenyl-GABA — Social Fear Can Vanish Long Before the Risk Becomes Obvious
What it is: Phenibut is β-phenyl-GABA, an unapproved and unregulated GABA-B-active drug sold mainly as the hydrochloride salt or free amino acid. The phenyl group helps it reach the brain; the R-enantiomer appears to carry most of its relevant activity.
What it may feel like: When it works, the internal editor that normally asks, “Was that awkward? Do they dislike me?” can become almost silent. Conversation feels automatic, music and touch may feel warmer, and confidence can resemble being pleasantly drunk without initially feeling drunk. The trap is that onset is so delayed that users redose, then encounter heavy sleep, poor coordination, a next-day “afterglow,” or—after repeated use—rebound terror, insomnia, tremor, hallucinations, and seizures.
The simplest description: Phenibut can make social fear feel irrelevant for a day, then make the brain demand repayment when it is repeated.
How It Works
Phenibut primarily activates metabotropic GABA-B receptors, which reduce presynaptic calcium entry and transmitter release; the active enantiomer may also bind α2δ calcium-channel subunits. It reaches the CNS but does not selectively turn off anxiety: motor control, memory, arousal, breathing, and reward can be affected alongside fear.
Dose and How It Is Taken
There is no established safe nootropic dose or cycle. Older clinical literature used formulation-specific doses under medical systems that do not establish safety for gray-market powder. Because the HCl and free-amino-acid forms have different mass and handling, scoop measurement and casual conversion are especially unreliable.
Phenibut HCl is water-soluble and commonly swallowed in water or capsules; this describes handling, not a recommendation. Reliable human food-effect data are lacking, so “empty stomach” rules are forum convention rather than validated optimization. Do not mistake a slow onset for a failed dose, and never combine it with alcohol, opioids, benzodiazepines, Z-drugs, baclofen, gabapentinoids, or other depressants.
Timing and Pharmacokinetics
Modern evidence for healthy cognition is weak. In contrast, systematic reviews of human toxicity and withdrawal cases document delirium, hallucinations, severe agitation, and seizures. Forum accounts repeatedly describe a delayed but unusually strong removal of social inhibition, while nonresponders report nothing but nausea, wobbliness, constipation, or anxiety; anecdotes cannot provide incidence or a safe schedule. Phenibut withdrawal systematic review · Phenibut experience reports
Safety, Interactions, and Monitoring
Tolerance and physical dependence can develop rapidly, and withdrawal may be medically dangerous. Do not stop abruptly after repeated use without medical guidance. Urgent care is warranted for seizure, hallucinations, delirium, severe agitation, unstable vital signs, unresponsiveness, or breathing difficulty.
Product risk is unusually high: require identity, salt/form, enantiomeric composition, assay, and contaminant testing, though testing cannot make the dependence profile safe. Kidney impairment, sleep apnea, seizure vulnerability, pregnancy, unstable psychiatric illness, and substance-use history increase concern. Track exact product, time, objective coordination and memory, sleep, next-day mood, rebound anxiety, dose creep, and any desire to use it merely to feel normal.
Bottom Line
Phenibut’s appeal is vivid: it can make an anxious person experience social life without the usual internal alarm. Its delayed onset, reinforcement, tolerance, and potentially severe withdrawal make it a poor healthy-person nootropic and a particularly bad compound to improvise with.
What it is: Phenibut is β-phenyl-GABA, an unapproved and unregulated GABA-B-active drug sold mainly as the hydrochloride salt or free amino acid. The phenyl group helps it reach the brain; the R-enantiomer appears to carry most of its relevant activity.
What it may feel like: When it works, the internal editor that normally asks, “Was that awkward? Do they dislike me?” can become almost silent. Conversation feels automatic, music and touch may feel warmer, and confidence can resemble being pleasantly drunk without initially feeling drunk. The trap is that onset is so delayed that users redose, then encounter heavy sleep, poor coordination, a next-day “afterglow,” or—after repeated use—rebound terror, insomnia, tremor, hallucinations, and seizures.
The simplest description: Phenibut can make social fear feel irrelevant for a day, then make the brain demand repayment when it is repeated.
How It Works
Phenibut primarily activates metabotropic GABA-B receptors, which reduce presynaptic calcium entry and transmitter release; the active enantiomer may also bind α2δ calcium-channel subunits. It reaches the CNS but does not selectively turn off anxiety: motor control, memory, arousal, breathing, and reward can be affected alongside fear.
Dose and How It Is Taken
There is no established safe nootropic dose or cycle. Older clinical literature used formulation-specific doses under medical systems that do not establish safety for gray-market powder. Because the HCl and free-amino-acid forms have different mass and handling, scoop measurement and casual conversion are especially unreliable.
Phenibut HCl is water-soluble and commonly swallowed in water or capsules; this describes handling, not a recommendation. Reliable human food-effect data are lacking, so “empty stomach” rules are forum convention rather than validated optimization. Do not mistake a slow onset for a failed dose, and never combine it with alcohol, opioids, benzodiazepines, Z-drugs, baclofen, gabapentinoids, or other depressants.
Timing and Pharmacokinetics
- Subjective onset: Commonly two to five hours, sometimes longer.
- Pharmacologic onset / Tmax: A dependable formulation-specific human Tmax has not been established.
- Absorption/bioavailability: Orally active, but modern human bioavailability and equivalence among HCl, free-amino-acid, and racemic products are inadequately characterized.
- Full practical effect: Frequently reported around four to six hours, which explains premature redosing.
- Subjective duration: Often 12–24 hours, with a possible next-day tail despite a shorter reported plasma half-life.
- Half-life: One small human report is often cited at about 5.3 hours; the evidence base is too thin to treat this as precise.
- Accumulation/steady state: Repeated daily exposure can accumulate functionally and produce tolerance/dependence; a validated steady-state model is unavailable.
- Near-complete elimination: A five-half-life estimate would be roughly one day, but subjective effects and withdrawal can outlast plasma clearance.
- Metabolism/elimination: Limited data suggest substantial renal excretion unchanged; human metabolic mapping remains poor.
Modern evidence for healthy cognition is weak. In contrast, systematic reviews of human toxicity and withdrawal cases document delirium, hallucinations, severe agitation, and seizures. Forum accounts repeatedly describe a delayed but unusually strong removal of social inhibition, while nonresponders report nothing but nausea, wobbliness, constipation, or anxiety; anecdotes cannot provide incidence or a safe schedule. Phenibut withdrawal systematic review · Phenibut experience reports
Safety, Interactions, and Monitoring
Tolerance and physical dependence can develop rapidly, and withdrawal may be medically dangerous. Do not stop abruptly after repeated use without medical guidance. Urgent care is warranted for seizure, hallucinations, delirium, severe agitation, unstable vital signs, unresponsiveness, or breathing difficulty.
Product risk is unusually high: require identity, salt/form, enantiomeric composition, assay, and contaminant testing, though testing cannot make the dependence profile safe. Kidney impairment, sleep apnea, seizure vulnerability, pregnancy, unstable psychiatric illness, and substance-use history increase concern. Track exact product, time, objective coordination and memory, sleep, next-day mood, rebound anxiety, dose creep, and any desire to use it merely to feel normal.
Bottom Line
Phenibut’s appeal is vivid: it can make an anxious person experience social life without the usual internal alarm. Its delayed onset, reinforcement, tolerance, and potentially severe withdrawal make it a poor healthy-person nootropic and a particularly bad compound to improvise with.
26.4.2 Baclofen — A Medical GABA-B Brake, Not a Cleaner Phenibut
What it is: Baclofen is a prescription para-chlorophenyl-GABA drug used mainly for spasticity. It is a racemate, with most GABA-B activity attributed to R-baclofen, and it is not approved as a cognitive enhancer.
What it may feel like: Tight muscles may loosen and the body’s “ready to react” signal may drop. For some people that physical quiet also reduces anxiety; for others it feels like heavy limbs, dizziness, weakness, sleepiness, emotional flattening, or thinking through wet cement. It can remove a bodily problem that was consuming attention, but it does not create intelligence or clean focus.
The simplest description: Baclofen turns down motor and transmitter output; whether that feels like relief or impairment depends on what was too loud at baseline.
How It Works
It activates GABA-B receptors, reducing presynaptic calcium entry and increasing postsynaptic potassium conductance. The result is less excitatory transmitter release and less spinal motor excitability. It reaches the CNS, but much of its clinical value is expressed through reduced muscle tone; calm, coordination, alertness, and respiratory reserve cannot be separated perfectly.
Dose and How It Is Taken
Use only the prescribed tablet, solution, or suspension and the clinician’s titration plan. There is no nootropic dose. Approved treatment is individualized, and kidney function can require major dose adjustment.
Baclofen is sufficiently water-soluble for oral solutions and suspensions. Modern liquid products show exposure similar to tablets, but formulations and concentrations are not casually interchangeable. Take consistently according to the product label; food optimization is less important than accurate dosing, renal adjustment, and avoiding other depressants.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence is strong for selected spasticity indications and inadequate for healthy cognitive enhancement. Reports outside those indications split between welcome physical calm and an unproductive state of weakness, sleepiness, or emotional dullness. Any apparent “focus” is usually indirect—pain, spasm, or physiological anxiety stopped interrupting the task—rather than a demonstrated pro-cognitive effect.
Safety, Interactions, and Monitoring
Tolerance and physical dependence can occur. Abrupt discontinuation after regular use can cause rebound spasticity, agitation, hallucinations, delirium, hyperthermia, muscle rigidity, and seizures; dose changes belong with the prescriber. Alcohol, opioids, benzodiazepines, Z-drugs, barbiturates, gabapentinoids, antihistamines, and other sedatives can produce nonlinear impairment or respiratory depression.
Use regulated product only. Kidney disease, older age/falls, respiratory disease or sleep apnea, pregnancy, seizure vulnerability, and unstable psychiatric or substance-use history require review. Track the target symptom, alertness, balance, memory, muscle strength, breathing, kidney function when indicated, next-day function, missed-dose symptoms, and any dose escalation.
Bottom Line
Baclofen can be highly useful when excessive muscle or neural output is the actual problem. In a healthy reader seeking sharper cognition, it is more likely to subtract alertness, strength, or memory than to add useful performance.
What it is: Baclofen is a prescription para-chlorophenyl-GABA drug used mainly for spasticity. It is a racemate, with most GABA-B activity attributed to R-baclofen, and it is not approved as a cognitive enhancer.
What it may feel like: Tight muscles may loosen and the body’s “ready to react” signal may drop. For some people that physical quiet also reduces anxiety; for others it feels like heavy limbs, dizziness, weakness, sleepiness, emotional flattening, or thinking through wet cement. It can remove a bodily problem that was consuming attention, but it does not create intelligence or clean focus.
The simplest description: Baclofen turns down motor and transmitter output; whether that feels like relief or impairment depends on what was too loud at baseline.
How It Works
It activates GABA-B receptors, reducing presynaptic calcium entry and increasing postsynaptic potassium conductance. The result is less excitatory transmitter release and less spinal motor excitability. It reaches the CNS, but much of its clinical value is expressed through reduced muscle tone; calm, coordination, alertness, and respiratory reserve cannot be separated perfectly.
Dose and How It Is Taken
Use only the prescribed tablet, solution, or suspension and the clinician’s titration plan. There is no nootropic dose. Approved treatment is individualized, and kidney function can require major dose adjustment.
Baclofen is sufficiently water-soluble for oral solutions and suspensions. Modern liquid products show exposure similar to tablets, but formulations and concentrations are not casually interchangeable. Take consistently according to the product label; food optimization is less important than accurate dosing, renal adjustment, and avoiding other depressants.
Timing and Pharmacokinetics
- Subjective onset: Often 30–90 minutes, though relief from spasticity may be judged over repeated doses.
- Pharmacologic onset / Tmax: About 0.75–1 hour for fasting oral liquid formulations.
- Absorption/bioavailability: Oral bioavailability is commonly estimated around 70–85%, with meaningful individual variation.
- Full practical effect: Usually within one to three hours for an acute dose; clinical titration takes longer.
- Subjective duration: Commonly four to eight hours.
- Half-life: About 5.6–5.7 hours in healthy adults; it can become much longer in renal impairment or overdose.
- Accumulation/steady state: Approximately one to two days with stable dosing and normal kidneys; impaired renal clearance can cause dangerous accumulation.
- Near-complete elimination: Roughly 28–35 hours by five half-lives in normal renal function.
- Metabolism/elimination: Limited metabolism; primarily excreted unchanged by the kidneys.
Evidence and Experiences
Evidence is strong for selected spasticity indications and inadequate for healthy cognitive enhancement. Reports outside those indications split between welcome physical calm and an unproductive state of weakness, sleepiness, or emotional dullness. Any apparent “focus” is usually indirect—pain, spasm, or physiological anxiety stopped interrupting the task—rather than a demonstrated pro-cognitive effect.
Safety, Interactions, and Monitoring
Tolerance and physical dependence can occur. Abrupt discontinuation after regular use can cause rebound spasticity, agitation, hallucinations, delirium, hyperthermia, muscle rigidity, and seizures; dose changes belong with the prescriber. Alcohol, opioids, benzodiazepines, Z-drugs, barbiturates, gabapentinoids, antihistamines, and other sedatives can produce nonlinear impairment or respiratory depression.
Use regulated product only. Kidney disease, older age/falls, respiratory disease or sleep apnea, pregnancy, seizure vulnerability, and unstable psychiatric or substance-use history require review. Track the target symptom, alertness, balance, memory, muscle strength, breathing, kidney function when indicated, next-day function, missed-dose symptoms, and any dose escalation.
Bottom Line
Baclofen can be highly useful when excessive muscle or neural output is the actual problem. In a healthy reader seeking sharper cognition, it is more likely to subtract alertness, strength, or memory than to add useful performance.
26.5 Alpha2delta Calcium-Channel Ligands
Gabapentin and pregabalin were designed as GABA analogues, but neither directly activates GABA-A or GABA-B receptors. They bind alpha2delta subunits of voltage-gated calcium channels and reduce activity-dependent excitatory transmitter release. The practical state can still feel inhibitory, and combination with opioids or other depressants can cause serious respiratory depression.
26.5.1 Gabapentin — It Can Quiet Pain and Hypervigilance, but the Absorption and Mental Fog Are Unpredictable
What it is: Gabapentin is a prescription α2δ calcium-channel ligand originally designed as a GABA analogue. Despite the name and shape, it does not directly activate GABA-A or GABA-B receptors.
What it may feel like: If nerve pain or hypervigilance has occupied half the screen in your mind, gabapentin can minimize that window and make ordinary work possible again. Some users describe calm clarity, better sleep, or even mild sociability; others feel drunk, clumsy, word-finding-impaired, exhausted, emotionally flat, or unable to hold a complex thought. The same reduction in neural “noise” that frees one person can become brain fog in another.
The simplest description: Gabapentin may return attention that pain or anxiety was stealing, but it can also dim the attention you were trying to recover.
How It Works
Gabapentin binds the α2δ-1 subunit of voltage-gated calcium channels and reduces activity-dependent release of excitatory transmitters. This means the effect is more evident when circuits are firing intensely—pain signaling, hyperarousal, or seizure activity—than when the brain is quiet. It reaches the CNS through amino-acid transport but is not selective for pain over balance, memory, or alertness.
Dose and How It Is Taken
Use only the prescribed formulation and renal-adjusted schedule. There is no healthy nootropic dose. Immediate-release gabapentin, gabapentin enacarbil, and gastric-retentive extended-release products have different food requirements and cannot be substituted milligram-for-milligram.
Immediate-release gabapentin is water-soluble and may be taken with or without food. Its intestinal transporter saturates, so a larger swallowed dose produces proportionally less absorption—not a proportionally larger brain effect. Antacids containing aluminum or magnesium reduce absorption and should be separated according to the label.
Timing and Pharmacokinetics
Evidence and Experiences
Evidence supports selected seizure and neuropathic-pain indications; anxiety use is off-label and healthy cognitive enhancement is unsupported. Forum experiences are unusually polarized: one person becomes calmer and finally able to focus because rumination or pain recedes, while another becomes “mushy,” sleepy, lost for words, or unable to perform familiar tasks. Those stories describe variability, not incidence. Gabapentin anxiety experiences
Safety, Interactions, and Monitoring
Tolerance to some subjective effects, misuse, physical dependence, rebound symptoms, and withdrawal can occur; regular use should not be stopped abruptly without medical advice. The FDA warns of serious respiratory depression in people combining gabapentin with opioids or other CNS depressants and in those with respiratory risk factors. Suicidal thoughts, severe confusion, allergic swelling, myoclonus/seizure, unresponsiveness, or slowed breathing require prompt care.
Use the exact regulated product. Kidney function is the main pharmacokinetic variable; age, edema/weight gain, sleep apnea, baseline cognitive load, and other sedatives also matter. Track the medical target, exact dose/time, pain or anxiety, objective word recall and task accuracy, balance, sleepiness, edema/weight, breathing, mood/suicidality, dose creep, and missed-dose symptoms.
Bottom Line
Gabapentin can improve real-world cognition indirectly when pain or pathological arousal is the bottleneck. If the bottleneck is not present—or the dose is too impairing—the result is usually not enhanced thinking but quieter, slower thinking.
What it is: Gabapentin is a prescription α2δ calcium-channel ligand originally designed as a GABA analogue. Despite the name and shape, it does not directly activate GABA-A or GABA-B receptors.
What it may feel like: If nerve pain or hypervigilance has occupied half the screen in your mind, gabapentin can minimize that window and make ordinary work possible again. Some users describe calm clarity, better sleep, or even mild sociability; others feel drunk, clumsy, word-finding-impaired, exhausted, emotionally flat, or unable to hold a complex thought. The same reduction in neural “noise” that frees one person can become brain fog in another.
The simplest description: Gabapentin may return attention that pain or anxiety was stealing, but it can also dim the attention you were trying to recover.
How It Works
Gabapentin binds the α2δ-1 subunit of voltage-gated calcium channels and reduces activity-dependent release of excitatory transmitters. This means the effect is more evident when circuits are firing intensely—pain signaling, hyperarousal, or seizure activity—than when the brain is quiet. It reaches the CNS through amino-acid transport but is not selective for pain over balance, memory, or alertness.
Dose and How It Is Taken
Use only the prescribed formulation and renal-adjusted schedule. There is no healthy nootropic dose. Immediate-release gabapentin, gabapentin enacarbil, and gastric-retentive extended-release products have different food requirements and cannot be substituted milligram-for-milligram.
Immediate-release gabapentin is water-soluble and may be taken with or without food. Its intestinal transporter saturates, so a larger swallowed dose produces proportionally less absorption—not a proportionally larger brain effect. Antacids containing aluminum or magnesium reduce absorption and should be separated according to the label.
Timing and Pharmacokinetics
- Subjective onset: Commonly one to three hours.
- Pharmacologic onset / Tmax: Approximately two to three hours for immediate release.
- Absorption/bioavailability: Saturable and dose-dependent; bioavailability falls from roughly 60% at lower divided doses toward about one-third at high daily exposures.
- Full practical effect: Acute sedation or calm clusters around two to four hours; pain/seizure benefit is evaluated over a stable regimen.
- Subjective duration: Often six to eight hours, with longer effects in kidney impairment.
- Half-life: About five to seven hours with normal kidneys; reported around 52 hours with severe renal impairment.
- Accumulation/steady state: Usually one to two days with normal renal function; markedly longer when clearance is impaired.
- Near-complete elimination: Roughly 25–35 hours normally, potentially many days with severe renal impairment.
- Metabolism/elimination: Not appreciably metabolized; excreted unchanged by the kidneys.
Evidence and Experiences
Evidence supports selected seizure and neuropathic-pain indications; anxiety use is off-label and healthy cognitive enhancement is unsupported. Forum experiences are unusually polarized: one person becomes calmer and finally able to focus because rumination or pain recedes, while another becomes “mushy,” sleepy, lost for words, or unable to perform familiar tasks. Those stories describe variability, not incidence. Gabapentin anxiety experiences
Safety, Interactions, and Monitoring
Tolerance to some subjective effects, misuse, physical dependence, rebound symptoms, and withdrawal can occur; regular use should not be stopped abruptly without medical advice. The FDA warns of serious respiratory depression in people combining gabapentin with opioids or other CNS depressants and in those with respiratory risk factors. Suicidal thoughts, severe confusion, allergic swelling, myoclonus/seizure, unresponsiveness, or slowed breathing require prompt care.
Use the exact regulated product. Kidney function is the main pharmacokinetic variable; age, edema/weight gain, sleep apnea, baseline cognitive load, and other sedatives also matter. Track the medical target, exact dose/time, pain or anxiety, objective word recall and task accuracy, balance, sleepiness, edema/weight, breathing, mood/suicidality, dose creep, and missed-dose symptoms.
Bottom Line
Gabapentin can improve real-world cognition indirectly when pain or pathological arousal is the bottleneck. If the bottleneck is not present—or the dose is too impairing—the result is usually not enhanced thinking but quieter, slower thinking.
26.5.2 Pregabalin — A More Predictable Gabapentinoid With a Stronger Calm and a Clearer Dependence Tradeoff
What it is: Pregabalin is a prescription α2δ calcium-channel ligand used for selected neuropathic-pain, seizure, and fibromyalgia indications; it is also approved for generalized anxiety disorder in some countries. It does not directly agonize GABA receptors.
What it may feel like: The fight-or-flight layer can slowly drain out of the body over one or two hours: the heart stops dominating awareness, conversation feels less threatening, and sleep may come more easily. Some people describe feeling normal, energetic, and socially present for the first time; others feel “stoned,” dizzy, blurred, emotionally distant, forgetful, or too dumb to trust their own work. Early euphoria can fade while tolerance, dose escalation, edema, weight gain, or missed-dose anxiety becomes more visible.
The simplest description: Pregabalin can make the alarm system stop interrupting everything, but it may also soften the precision of everything you do.
How It Works
Pregabalin binds α2δ-1 calcium-channel subunits and reduces activity-dependent release of glutamate, norepinephrine, substance P, and other transmitters. It is centrally active, but the effect is state-dependent: an overactive pain or anxiety circuit may normalize, while a normal circuit may simply become suppressed. It is not “GABA in a capsule.”
Dose and How It Is Taken
Use only a prescribed formulation and indication-specific, renal-adjusted schedule. There is no healthy nootropic dose. Immediate-release and extended-release products have different dosing and food instructions and are not interchangeable.
Pregabalin is water-soluble and rapidly absorbed. Immediate-release capsules may be taken with or without food: food lowers the peak by about 25–30% and delays Tmax to roughly three hours without materially changing total absorption. Consistency matters more than trying to maximize a “hit.”
Timing and Pharmacokinetics
Evidence and Experiences
Evidence is strong for labeled clinical indications and supports GAD in jurisdictions where approved; it does not establish healthy cognitive enhancement. Forum reports make the tradeoff vivid: racing heart and social self-monitoring may disappear enough to permit study or conversation, yet memory, coordination, and verbal sharpness can simultaneously fall. Initial “invincible” or euphoric responses often mellow, and nonresponse or worsening mood also occurs. Pregabalin anxiety experiences
Safety, Interactions, and Monitoring
Tolerance, misuse, physical dependence, withdrawal, and rebound anxiety or insomnia are established concerns; do not escalate to recapture the first-day feeling or stop regular use abruptly. The FDA warns of serious breathing problems with opioids, other depressants, underlying respiratory impairment, and older age. Alcohol, benzodiazepines, Z-drugs, barbiturates, baclofen, phenibut, sedating antihistamines, and gabapentin increase impairment.
Use regulated product only. Kidney disease, edema or heart-failure risk, sleep apnea, pregnancy, falls, substance-use history, and suicidality require review. Track the target symptom, exact timing, objective memory and work accuracy, balance/vision, sedation, edema and weight, breathing, mood, dose escalation, and symptoms before the next dose or after a missed dose.
Bottom Line
Pregabalin is more pharmacokinetically predictable than gabapentin and can be a legitimate treatment when anxiety or neuropathic pain is disabling. That does not make it a cognition drug: benefit comes from removing a pathological bottleneck, and the price may be fog, tolerance, or dependence.
What it is: Pregabalin is a prescription α2δ calcium-channel ligand used for selected neuropathic-pain, seizure, and fibromyalgia indications; it is also approved for generalized anxiety disorder in some countries. It does not directly agonize GABA receptors.
What it may feel like: The fight-or-flight layer can slowly drain out of the body over one or two hours: the heart stops dominating awareness, conversation feels less threatening, and sleep may come more easily. Some people describe feeling normal, energetic, and socially present for the first time; others feel “stoned,” dizzy, blurred, emotionally distant, forgetful, or too dumb to trust their own work. Early euphoria can fade while tolerance, dose escalation, edema, weight gain, or missed-dose anxiety becomes more visible.
The simplest description: Pregabalin can make the alarm system stop interrupting everything, but it may also soften the precision of everything you do.
How It Works
Pregabalin binds α2δ-1 calcium-channel subunits and reduces activity-dependent release of glutamate, norepinephrine, substance P, and other transmitters. It is centrally active, but the effect is state-dependent: an overactive pain or anxiety circuit may normalize, while a normal circuit may simply become suppressed. It is not “GABA in a capsule.”
Dose and How It Is Taken
Use only a prescribed formulation and indication-specific, renal-adjusted schedule. There is no healthy nootropic dose. Immediate-release and extended-release products have different dosing and food instructions and are not interchangeable.
Pregabalin is water-soluble and rapidly absorbed. Immediate-release capsules may be taken with or without food: food lowers the peak by about 25–30% and delays Tmax to roughly three hours without materially changing total absorption. Consistency matters more than trying to maximize a “hit.”
Timing and Pharmacokinetics
- Subjective onset: Commonly one to two hours.
- Pharmacologic onset / Tmax: About 1.5 hours fasting and around three hours with food.
- Absorption/bioavailability: At least 90%, dose-independent, and more linear/predictable than gabapentin.
- Full practical effect: Acute calm or impairment is often clearest around two to four hours; clinical anxiety or pain response is assessed over days to weeks.
- Subjective duration: Commonly six to twelve hours, depending on dose and renal function.
- Half-life: Approximately 6.3 hours with normal kidneys.
- Accumulation/steady state: Reached in about 24–48 hours with repeated dosing.
- Near-complete elimination: Roughly 30–36 hours in normal renal function, longer with kidney impairment.
- Metabolism/elimination: Negligible metabolism; excreted mostly unchanged in urine.
Evidence and Experiences
Evidence is strong for labeled clinical indications and supports GAD in jurisdictions where approved; it does not establish healthy cognitive enhancement. Forum reports make the tradeoff vivid: racing heart and social self-monitoring may disappear enough to permit study or conversation, yet memory, coordination, and verbal sharpness can simultaneously fall. Initial “invincible” or euphoric responses often mellow, and nonresponse or worsening mood also occurs. Pregabalin anxiety experiences
Safety, Interactions, and Monitoring
Tolerance, misuse, physical dependence, withdrawal, and rebound anxiety or insomnia are established concerns; do not escalate to recapture the first-day feeling or stop regular use abruptly. The FDA warns of serious breathing problems with opioids, other depressants, underlying respiratory impairment, and older age. Alcohol, benzodiazepines, Z-drugs, barbiturates, baclofen, phenibut, sedating antihistamines, and gabapentin increase impairment.
Use regulated product only. Kidney disease, edema or heart-failure risk, sleep apnea, pregnancy, falls, substance-use history, and suicidality require review. Track the target symptom, exact timing, objective memory and work accuracy, balance/vision, sedation, edema and weight, breathing, mood, dose escalation, and symptoms before the next dose or after a missed dose.
Bottom Line
Pregabalin is more pharmacokinetically predictable than gabapentin and can be a legitimate treatment when anxiety or neuropathic pain is disabling. That does not make it a cognition drug: benefit comes from removing a pathological bottleneck, and the price may be fog, tolerance, or dependence.
@Volpa #Volpamogs
Last edited:
